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Abstract: Meroterpenes are widely distributed among marine organisms; they are 
particularly abundant within brown algae, but other important sources include 
microorganisms and invertebrates. In the present review the structures and bioactivities of 
meroterpenes from marine invertebrates, mainly sponges and tunicates, are summarized. 
More than 300 molecules, often complex and with unique skeletons originating from  
intra- and inter-molecular cyclizations, and/or rearrangements, are illustrated. The reported 
syntheses are mentioned. The issue of a potential microbial link to their biosynthesis is also 
shortly outlined. 
Keywords: meroterpenes; terpene quinone; terpene hydroquinone; sponges; ascidians;  
soft corals 
 
1. Introduction 
Quinones are ubiquitous in nature, occurring as secondary metabolites in many organisms; often they 
are molecules essential to life, being intimately related to the oxidative processes in cells [1]. 
Polyprenylated 1,4-benzoquinones and hydroquinones, such as ubiquinones, plastoquinones, and 
tocopherols, are widespread in plants and animals, in which they play important roles in electron 
transport, photosynthesis, and as antioxidants [1,2]. Terpene quinone/hydroquinone natural products 
differing from the above-mentioned groups frequently occur as secondary metabolites in many 
organisms; they form a class of complex metabolites, generally called meroterpenes, of mixed 
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biosynthetic origin which are partially derived from terpenoids. In addition to their wide occurrence, 
meroterpenes display a huge range of structural diversity, with structures varying from simple 
compounds comprising a prenyl unit linked to the hydroquinone unit to unique architectural scaffolds, 
often linked with varied functionalities, arising from intra- and intermolecular ring closures and/or 
rearrangements of the terpene chains. Moreover, they display important biological activities, 
undoubtedly related to their most prominent chemical feature, that is their ability to undergo redox 
cycling to generate reactive oxygen species (ROS) which can damage cells [3,4]. 
In the marine environment, meroterpenes have been isolated mainly from brown algae and 
microorganisms, but another important source are marine invertebrates, mainly sponges and tunicates. 
The present review provides an update on the meroterpenes so far isolated from marine invertebrates; it 
describes the structures and biological activities of 300 natural products, thus highlighting the structural 
diversity generated in this class of natural products and their potential in drug discovery. The issue of a 
potential microbial link to their biosynthesis is also shortly outlined. 
2. Meroterpenes from Ascidians 
While the majority of metabolites isolated from ascidians are nitrogen-containing compounds 
(alkaloids or peptide related compounds), ascidians belonging to the genus Aplidium are known as a rich 
source of meroterpenes [5–7]. The first biologically active tunicate metabolite was indeed 
geranylhydroquinone (2), isolated from an Aplidium sp. and, successively, found in many others 
Aplidium species; it was shown to offer protection against leukemia and tumor development in test 
animals [8]. Several linear diprenylquinones/hydroquinones (compounds 1–17, Figure 1) have been then 
reported from diverse Aplidium species (A. multiplicatum [9], A. savigny [10], A. conicum [11],  
A. glabrum [12], A. scabellum [13], Aplidium spp. [14,15]); the majority of them possess a linear side 
chain of the geranyl type with rare examples of neryl derivative such as verapliquinone D (13), 
verapliquinone B (14), and glabruquinone B (15). A. californicum has been the source of the simple 
monoprenyl derivatives 1 and 9 which were identified as anticancer and antimutagenic agents [16]. 
Glabruquinone A (3-demethylubiquinone Q2, 11) is closely related to the ubiquinones, although lacking 
the methyl group in the quinoid moiety; it is not a cytotoxin but demonstrated good cancer preventive 
activity on JB6 Cl 41 cell transformation activated by epidermal growth factor (EGF). Structure-activity 
relationships studies on its synthetic analogs demonstrated that this activity depend on the length of the 
side chain and on the position of the methoxyl groups in the quinone part of the molecule [17]. In vivo, 
anticancer properties of 11 and its synthetic analogs, as well as the molecular mechanism of its action 
against tumor cells, have been examined; it was shown to inhibit the growth of the solid Ehrlich 
carcinoma in mice and to induce apoptosis in various human tumor cell lines [18]. Both 
2-geranyl-6-methoxy-1,4-hydroquinone-4-sulfate (17) and the triprenylated (farnesyl) hydroquinone 
rossinone A (8) were found to be active in an anti-inflammatory assay, in vitro, with activated  
human peripheral blood neutrophils; they inhibit the superoxide production when either 
N-formyl-methionyl-leucyl-phenilalanine (fMLP) or phorbol myristate acetate (PMA) were used to 
activate the respiratory burst [13,15]. The monoprenylhydroquinone 1 and geranylhydroquinone 2 were 
also active in the same assay [15], indicating that prenyl quinones could indeed hold promise for the 
development of new anti-inflammatory agents. 
Mar. Drugs 2013, 11 1604 
 
 
Figure 1. Quinones and hydroquinones linked with linear prenyl chains. 
 
Several interesting classes of cyclic, polycyclic, macrocyclic, and/or dimeric prenyl 
quinones/hydroquinones are reported to occur in marine ascidians. The biosynthetic origin of these 
compounds has been largely speculated about; they clearly arise from corresponding derivatives with 
linear prenyl chains that are usually isolated concomitantly from the natural source. Ortho-prenylated 
quinones can undergo different chemical transformations, ranging from cascade cyclization reactions 
involving carbocation species [19] to pericyclic reactions, such as electrocyclizations or cycloadditions, 
via ortho-quinones methide intermediates [20]. However, with the data available, it is not possible to 
argue whether the above mentioned transformations occur in the organism, prior to its extraction, either 
enzymatically (in nature dehydrogenase enzymes appear to catalyze such processes [21]) or not, or that 
they take place during isolation and/or chromatographic purification. 
Cyclodiprenyl hydroquinones/quinones (Figure 2) have been isolated from A. aff. densum 
(methoxyconidiol, 18) [22] and from A. conicum (conitriol, 19, and conidione, 20) [11]. 
Methoxyconidiol (18) displayed an antimitotic action on the first division of sea urchin embryos, 
disrupting M-phase progression and completely blocking cytokinesis without having any effect on  
DNA replication [23]. 
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Figure 2. Cyclodiprenyl hydroquinones/quinones. 
 
The occurrence of chromene (2H-benzopyran) derivatives as natural products has been reported in  
A. californicum (21) [14], A. costellatum (22) [24], A. multiplicatum (23) [9], A. scabellum (24) [13], and 
A. solidum (25 and 26) [25]. The chromane derivative 27 has been isolated from Synoicum costellatum [26], 
a species closely allied to the genus Aplidium, and successively found in A. conicum together with its 
C-1′ epimer, conicol (28) [11]. Didehydroconicol (29) has been isolated from A. aff. densum [22]. 
Tuberatolides (30 and 31) and sargachromenols (32 and 33), isolated from Botryllus tuberatus along 
with their putative linear precursor yezoquinolide (16), antagonized the chenodeoxycholic acid 
(CDCA)-activated human farnesoid X receptor (hFXR), a ligand-dependent transcription factor in the 
nuclear receptor superfamily which has been recently identified as a promising drug target in the 
treatment of atherosclerosis [27]. Longithorol E (34), from A. longithorax, is a unique macrocyclic 
chromenol containing a new 14 membered carbocycle [28] (Figure 3). 
Figure 3. Chromene (2H-benzopyran) derivatives. 
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Rossinone B (35) is a triprenylated (farnesyl) quinone first isolated from an Antarctic Aplidium sp. [15] 
and successively recovered in the viscera extract of A. fugiense, also collected in Antarctica, along with 
the related compounds 36–38 [29] (Figure 4). Rossinone B has a rather novel structural architecture 
featured by a linearly fused 6-6-5-ring core, which so far has been found in only three plant-derived 
natural products, pycnanthuquinones A–C [19,30]. The tricyclic framework of 35 supposedly derive 
from the corresponding linear hydroquinone derivative rossinone A (8) which has been reported  
to co-occurr in Aplidium sp. [15]. Interestingly, neither acyclic hydroquinones nor putative 
quinone-containing precursors of compounds 35–38 were detected in A. fugiense extract [29]. Rossinone 
B (35) exhibited anti-inflammatory, antiviral, and antimicrobial activities [15]. Attracted by its novel 
chemical structure, promising biological properties and potentially intriguing biosynthetic pathway, a 
biomimetic total synthesis of (±)-rossinone B has been achieved through a highly efficient strategy 
featuring a series of rationally designed reactions, including an intramolecular vinyl quinone 
Diels-Alder reaction to construct the linear 6-6-5 tricyclic core of 35 [31]. 
Figure 4. Cyclic triprenylated quinone/hydroquinones. 
 
A. longithorax has been the source of longithorones and longithorols, a group of farnesylated 
quinone/hyroquinones featuring unprecedented macrocylic skeletons derived formally by the rarely 
encountered cyclization of farnesyl quinones/hydroquinones to give [9]- and [10]metacyclophane, as 
well as [12]paracyclophane structures [28,32–35]. Longithorones B–D (39–41), J (42), and K (43) 
together with longithorols C (44) and D (45), are monomeric C21 compounds (Figure 5). Longithorol C 
(44) could undergo an intramolecular cyclization, followed by dehydration, to yield the chromenol 
longithorol E (34), which is possibly an artifact of the isolation process. A short synthetic approach to the 
macrocyclic framework of longithorone C has been described via ring-closing metathesis using  
the Grubbs second generation catalyst [36]. Longithorone J (42) is the first example of a 
γ-hydroxy-cyclohexenone in this class of compounds. Floresolides A–C (46–48) are three further 
monomeric cyclofarnesylated hydroquinones isolated from an Indonesian Aplidium sp. They are unique 
members of the longithorone/longithorol class of meroterpenes, having an endocyclic ε-lactone bridging 
the aromatic ring and a [10]metacyclophane moiety. Floresolides showed moderate cytotoxicity against 
KB cells [37]. 
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Figure 5. Monomeric meta- and paracyclophane type meroterpenes. 
 
Longithorones A (49) and E–I (50–54) are dimeric compounds (Figure 6). Compounds 49–54, as well 
as the monomeric longithorones 39–43, exhibit atropisomerism arising from hindered rotation of 
quinone ring through their macrocyclic rings. The biosynthesis of dimeric longithorones, which have 
been supposed to originate by both intra- and intermolecular Diels-Alder reactions, has been speculated 
about. Fusion of the two farnesyl-quinone units can be envisioned as arising via a Diels-Alder 
cycloaddition of suitably unsaturated precursors, whereas rings B and C could arise by a transannular 
Diels-Alder reaction. The co-isolation of the monomers 39–43 provides some support for this proposal. 
The stereochemistry of the central carbocyclic rings in 35 and 39–43 is consistent with such a fusion [34]. 
An enantioselective biomimetic synthesis of longithorone A has been accomplished, which 
demonstrates the feasibility of the reactions proposed for the biosynthesis-albeit using non-enzymatic 
conditions. The challenge of a synthesis of longithorone A was heightened by the presence of two forms 
of chirality: the stereogenic centers present in the tricyclic core portion of the molecule and 
atropisomerism. The synthesis presents a unique example of chirality transfer in complex molecule 
synthesis involving the use of stereogenic centers to control atropisomerism, removal of the stereogenic 
centers, and transfer of the atropisomerism back to stereogenic centers in the natural product [38]. 
Longithorols A (55) and B (56) represent the first examples of hydroquinones in the [12]paracyclophane 
structure class. They were isolated as their pentaacetates because of their rapid decomposition  
occurring under purification conditions [35]. To date, the only biological activity reported for 
longithorones/longithorols class of marine metabolites pertains to longithorone A (49), which was 
shown to display cytotoxicity against P388 murine leukaemia cells. 
Further examples of pseudodimeric meroterpenoids are scabellones A–D, (57–60) isolated from  
A. scabellum [13], possessing a benzo[c]chromene-7,10-dione scaffold particularly rare among natural 
products (Figure 7). Scabellone B (58) was found to inhibit the superoxide production by 
PMA-stimulated human neutrophils in vitro; it was also evaluated against the neglected disease parasites 
targets Trypanosoma brucei rhodesiense, T. cruzi, Leishmania donovani, and Plasmodium falciparum 
and exhibited selectivity toward Plasmodium falciparum (K1 chloroquine-resistant strain) with  
IC50 4.8 μM and only poor cytotoxicity (L6 rat myoblast cell line, IC50 65 μM) [13]. 
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Figure 6. Dimeric paracyclophane type meroterpenes. 
 
Figure 7. Dimeric benzo[c]chromene-7,10-dione containing meroterpenes. 
 
A sample of A. conicum collected along Sardinia coasts gave rise to the isolation of a large group of 
unique prenylated thiazinoquinones, namely conicaquinones A and B (61 and 62) [39], aplidinones A–C 
(63–65) [40], and thiaplidiaquinones A and B (66 and 67) [41] (Figure 8). All these meroterpenes feature 
an unusual 1,1-dioxo-1,4-thiazine ring fused with the quinone portion. Aplidinones A–C (63–65) and 
conicaquinones A and B (61 and 62) possess a benzoquinones and a naphtoquinone moiety, respectively. 
Thiaplidiaquinones A and B (66 and 67) possess an unprecedented tetracyclic core, visibly composed of 
two geranylated benzoquinones that have fused together, whose biosynthetic origin has been speculated 
to stem from hypotaurine addition to tricyclic pyranoquinones derived from oxa-6π-electrocyclization of 
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ortho-quinone methide tautomers of bis-benzoquinones [42]. Based on this premise, two biomimetic 
synthesis of the thiaplidiaquinones scaffold have been reported [42,43]. In a first concise total synthesis 
of thiaplidiaquinone A, the key ring forming steps are both based on biosynthetic considerations and 
involve the construction of the central benzo[c]chromene quinone unit by an extremely facile 
oxa-6π-electrocyclic ring closure reaction of an ortho-quinone intermediate, derived by tautomerization 
of a bis-benzoquinone, readily accessed from two simple phenolic precursors. This is followed by the 
installation of the 1,4-thiazine-dioxide ring by reaction of the benzo[c]chromene quinone with 
hypotaurine [43]. An alternative biomimetic synthesis of both thiaplidiaquinones A and B has been 
reported where bis-benzoquinones construction, instead of via a Suzuki-Miyaura reaction [43], was 
achieved simply by base-mediated dimerization of geranylbenzoquinone. Subsequent reaction with 
hypotaurine yielded the dioxothiazine regioisomers of thiaplidiaquinones A and B [42]. Both 
conicaquinones A and B showed a marked and selective cytotoxic effects on rat glioma cells [40], and 
thiaplidiaquinones were strongly cytotoxic against Jurkat cell line, derived from a human T lymphoma, 
inducing cell death by apoptosis [41]. The pro-apoptotic mechanism of thiaplidiaquinones involves the 
induction of a strong production of intracellular reactive oxygen species (ROS) in the cells, likely due to 
the inhibition of the plasma membrane NADH-oxidoreductase (PMOR) system, an important target for 
anticancer drugs, through interference with the coenzyme-Q binding site [41]. In order to validate the 
structural assignment made for aplidinones by theoretical means a synthetic approach has been 
undertaken which yielded some synthetic analogs of aplidinone A in which the geranyl chain is replaced 
by other alkyl chains [44]; these compounds as well as the natural metabolite 63 were subjected to 
cytotoxicity assays and preliminary structure-activity relationships (SAR) studies. Both aplidinone A 
and its synthetic analogs were shown to possess interesting cytotoxic effects; SAR studies revealed that 
cytotoxic activity depends on the nature and the length of side chain linked to the benzoquinone ring and, 
mainly, on its position respect to the dioxothiazine ring. The study also evidenced one of the synthetic 
analogs as a potent cytotoxic and pro-apoptotic agent against several tumor cell lines, which also inhibits 
the TNFα-induced NF-κB activation in a human leukemia T cell line [44].  
Figure 8. Prenylated thiazinoquinones from A. conicum. 
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3. Meroterpenes from Sponges 
Marine sponges have yielded a huge variety of meroterpenes having a terpenoid skeleton varying 
from sesqui-, di-, sester- or triterpene units. 
The large class of sesquiterpene quinones isolated from various species of marine sponges, has 
attracted the attention of researchers because of their biological properties, including antimicrobial [45], 
antileukemic [46], anti-malarial [47], immunomodulatory [48,49], and anti-HIV [50] activities. Above 
all, the cytotoxic and antiproliferative properties of many sesquiterpene quinones/hydroquinones isolated 
from sponges have supported several studies for the development of new antitumor agents [51,52]. 
A large family of antineoplastic compounds, named metachromins (68–87), has been isolated from 
sponges of the genus Spongia, Thorecta and Hippospongia (Figure 9) [53–58]. They exhibited potent 
antitumor activity against L1210 murine leukemia cells in vitro. Metachromins A–C (68–70) showed 
also potent coronary vasodilating activity, markedly inhibiting KCl (40 mM) induced contraction of the 
rabbit isolated coronary artery with an IC50 value of 3 × 10
−6
 M each. While metachromins D–H (71–75) 
exhibited cytotoxity against human epidermoid carcinoma KB cells with IC50 values of 10, 0.4, 1.9, >10, 
and 6.4 μg/mL, respectively. Metachromins L (76), M (77), S (83), and T (84) showed cytotoxicity 
against L1210 murine leukemia (IC50, 4.0, 3.5, 5.2 and 3.0 μg/mL, respectively) and KB human 
epidermoid carcinoma cells (IC50, 4.0, 5.4, >10 and 5.6 μg/mL, respectively) in vitro, while 
metachromins N–R (78–82) did not show such activity (IC50 > 10 μg/mL). Metachromins U–W (85–87) 
were screened against four human tumor cell lines [MCF-7 (breast), SF-268 (CNS), H-460 (lung), and 
HT-29 (colon)], as well as a mammalian cell line [Chinese hamster ovary (CHO-K1) cells]. All three 
compounds were found to be cytotoxic against all cell lines, with 86 being the most active. Surprisingly, 
87, possessing a napthoquinone functionality, which is known to impart significant cytotoxic properties 
to various molecules [58], was significantly less active than both 85 and 86. Interestingly, metachromins 
N–R (78–82) [57], which contain both quinone and phenol functions, are inactive, most likely due to 
the bulky nature of the substituents present on the quinone portion. 
In fact, most of sesquiterpene benzo(hydro)quinone isolated from sponges possess a decalin 
structure, consisting of a drimane or 4,9-friedodrimane skeleton, connected to the quinone/hydroquinone 
moiety generally via one carbon-carbon bonding. Particularly prolific sources of this sort of 
meroterpenes are marine sponges belonging to the Dysidea genus. 
Compounds having a typical 4,9-friedodrimane skeleton are shown in Figure 10. Avarol (88) and its 
quinone derivative avarone (89) have been isolated from the marine sponge Dysidea avara [59,60]; the 
absolute stereochemistry of 88, which has been stated by spectroscopic and chemical methods in 1976 [61] 
was later confirmed by crystallographic analysis [62]. Both compounds were discovered as 
anti-leukemia agents in vitro and in vivo [46,63–66], and later it was found that they had an inhibitory 
capacity in vitro against HIV-1 [66–68]. Various formulations with high avarol content have been used 
for the prevention and treatment of psoriasis, dermatitis, skin cancer, tumors in the gastrointestinal tract, 
urinary tract, and viral infection [69]. Their potent T-lymphotropic cytostatic activity, low toxicity in 
mice, the ability to cross the blood-brain barrier and the capacity to stimulate the synthesis of interferon 
make both these compounds optimum candidates for transformations aimed at improving their cytostatic 
and antiviral activity [63–69]. 
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Figure 9. Metachromins. 
 
Figure 10. 4,9-Friedodrimane-type skeleton containing meroterpenes of the  
avarol/avarone series. 
 
A number of derivatives of avarol and avarone have been isolated from other Dysidea species. 
Examples are neoavarol (90), neoavarone (91), 4′-methoxyavarone (92) and 4′-methoxyneoavarone (93), 
isolated from a sample of Dysidea sp. collected in Okinawa [70], and 6′-hydroxyavarol (94), 
6′-acetoxyavarol (95), 3′-hydroxyavarone (96), 6′-acetoxyavarone (97), 3′,6′-dihydroxyavarone (98) and 
6′-hydroxy-4′-methoxyavarone (99), isolated from Dysidea cinera [71]. Some of these compounds 
Mar. Drugs 2013, 11 1612 
 
 
showed cytotoxic activity, 3′-hydroxyavarone (96), 6′-acetoxyavarol (95) and 3,6′-dihydroxyavarone 
(98) exhibiting high potency against P-388 mouse lymphoma. From different extracts of Dysidea avara 
collected from different places (Japan, the Solomon Islands, and others), mono-(100), diacetyl-(101), 
and 6′-hydroxy-5′-acetylavarol have been isolated [49,72,73]. A number of avarol derivatives exhibited 
interesting activity in enzyme assays measuring inhibition of various functions of HIV-1 reverse 
transcriptase [74]. 
From the Pacific sponge Dysidea arenaria, a pair of mildly cytotoxic compounds, arenarol (102) and 
arenarone (103), have been isolated having the same rearranged sesquiterpene skeleton as avarol, but 
with cis- rather than trans-decalin stereochemistry [75]. 
Ilimaquinone (104), first isolated from the Hawaiian sponge Hippospongia metachromia [76] and 
successively recovered in several other sponge species along with its 5-epi-analogous (105) and both 
isospongiaquinone (106) and 5-epi-isospongiaquinone (107) [77–80]. In 1987 Capon reversed the 
absolute stereochemistry of (−)ilimaquinone, placing (+)arenarol and (−)ilimaquinone in the same  
8S,9R absolute stereochemical series [81]. Several important activities have been reported for 
ilimaquinone, including anti-HIV activity [50] and ability to protect cells from the toxic effects of ricin 
and diphtheria toxin [82]. Particularly, it has been suggested that 104 induces a concentration-dependent 
antiproliferative effect in several types of cancer cell lines. The anticancer mechanism of ilimaquinone 
in the representative PC-3 cells was identified; it induces a time-dependent increase in G1 phase arrest 
and a subsequent increase in the hypodiploid sub-G1 phase (apoptosis) of the cell cycle. Although 
ilimaquinone-induced Golgi vesiculation [83,84], the data showed that the inhibition of cancer cell 
growth did not occur through Golgi fragmentation. Ilimaquinone (104) also inhibited the DNA binding 
of NF-κB; however, this inhibitory effect cannot explain the ilimaquinone-induced anticancer effect. In 
brief, it is suggested that ilimaquinone (104) induces its antiproliferative effect through the G1 arrest of 
the cell cycle and the up-regulation and nuclear translocation of CHOP/GADD153 [85]. 
5-epi-Ilimaquinone (105) showed cytotoxic activity against P-388 leukemia cells (2.2 μg/mL) and 
different solid tumors: A-549 (0.9 μg/mL), HT-29 (3.4 μg/mL) and B16/F10 (1.1 μg/mL) [80]. 
Bolinaquinone (108) is a cytotoxic sesquiterpene isolated from a Dysidea sponge in which quinone 
moiety is located on an unusual carbon of the 4,9-friedodrimane skeleton [86]. This compound was 
cytotoxic against HCT-116 human colon carcinoma (IC50 = 1.9 μg/mL) and it has been demonstrated to 
act by interfering with or damaging DNA. 21-dehydroxybolinaquinone (109), isolated from the Hainan 
sponge Dysidea villosa, showed moderate PTP1B inhibitory activity and cytotoxicity, with IC50 values 
of 39.5 and 19.5 mM, respectively [87]. 
Examples of meroterpenes of the drimane series (Figure 11) are dactylospongiaquinone (110) and 
spongiaquinone (111), isolated from the sponge Dactylospongia n. sp. [79,88], isohyatellaquinone 
(112), dictyoceratidaquinone (113), mamanuthaquinone (114), and hyatellaquinone (115) from both 
Dactylospongia and Fasciospongia sponges [89–92]. Total synthesis of both hyathellaquinone (115) 
and spongiaquinone (111) has been reported [93,94]; particularly, synthesis of (−)-hyatellaquinone led 
to revision of absolute configuration of the naturally occurring (+)-isomer [93]. The anti-inflammatory 
sesquiterpene-quinone 116 has been isolated from the New Zealand sponge Dysidea cf. cristagalli [95]. 
Wiedendiols A (117) and B (118) were isolated from the marine sponge Xestospongia wiedenmayeri, 
collected in the Bahamas [96].
 
The CETP-SPA inhibition assays carried out with these compounds 
revealed an IC50 = 5 μM in both cases. Later, the inhibition of CETP was verified using a precipitation 
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method to separate lipoproteins after incubation of HDL radiolabeled with LDL and CETP. In this assay, 
both 117 and 118 had an IC50 of 1.0 and 0.6 μM, respectively. Wiedendiol B is a ten-fold stronger 
inhibitor of cyclooxigenase-2 than the reference compound indomethacine [97]. 
Smenodiol (119), isolated from a Seychellean sponge belonging to the genus Smenospongia [98], and 
compounds 120 and 121, isolated from Dactylospongia elegans [80], feature a carboxilate function on 
the aromatic ring; smenodiol could be considered a possible direct precursor of pelorol (122), isolated 
from D. elegans [99], as it is a simple cyclization product thereof (Figure 11). 
Figure 11. Drimane-type skeleton containing meroterpenes. 
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An aldehyde function is the distinctive feature of siphonodictyals A–D (123–126), G (127), B2 (128), 
and B3 (129), which have been isolated from Siphonodictyon species along with the relevant  
alcohols siphonodictyols G (130) and H (131) and siphonodictyoic acid (132); most of them were 
sulfated [100–102]. The isolated compounds were tested for antimicrobial activity (antibacterial, 
antifungal); it has been suggested that the different substituents on the aromatic moieties have an impact 
on activity and that the ortho-hydroquinone structure may be the active center of the molecules. It is 
likely that the hydroquinone is oxidized in the metabolism of the assay organisms to yield the more toxic 
ortho-quinone. 
The presence of aminoquinone compounds is not very common in natural products; however, several 
sesquiterpenes quinones/hydroquinones, with such a drimane or a 4,9-friedodrimane, where the 
aromatic fragment is substituted with simple amines and amino acids have been isolated from sponges 
(Figures 12 and 13). The sesquiterpene aminoquinones smenospongine (133), smenospongiarine (134), 
smenospongidine (135), and their corresponding 5-epimers 136–138, have been isolated from different 
sponge species [47,70,103,104]. Erythroid differentiation of K562 cells induced by compounds 133–138 
and other related compounds has been studied.
 
On the basis of structure–activity relationship studies, the 
following evidences were obtained: (a) the quinone structure is indispensable; (b) the amino group should 
play an important role; (c) the substituents at the amino group are not crucial; (d) the configuration at the 
C-5 in sesquiterpene part is not important [105,106]. Smenospongines B (139) and C (140) were isolated 
from D. elegans collected in Australia along with the sesquiterpene benzoxazole nakijinol B (141) and 
its diacetyl derivative 142 [107]. The biological activities of these compounds were established against a 
panel of human tumor cell lines, as well as a normal mammalian cell line. The compounds were found to 
have cytotoxic activities in the range 1.8–46 μM and appeared to lack selectivity for tumor versus 
normal cell lines. The presence of two bulky acetate moieties resulted in an approximate two-fold 
increase in the activity of 142 compared to the diol 141. One possible explanation for this increase in 
activity is that the acetate groups may contribute to greater bioavailability through enhanced membrane 
permeation after which metabolism, possibly hydrolysis by esterases, releases the active compounds 
intracellularly [108]. For 139 and 140, the additional methylene in the nitrogen-substituted side chain 
had the effect of reducing observed activity by a factor of 2 (Figure 12). 
From different extracts of Dysidea avara collected from different places (Japan, the Solomon Islands, 
and others), melemeleone A (143), melemeleone B (144) have been isolated possessing a taurine moiety 
linked to the quinone ring. Melemeleone B (144) was proved to have a certain activity against PTK 
(Protein Tyrosine Kinase) pp60
v-sarc
 (dose: 20 μg/mL) with an IC50 = 28 μM [49]. Dysidine (145), found 
in the Hainan sponge Dysidea villosa, also features a taurine residue on the aromatic portion, which is 
otherwise connected at C-11 of the decalin ring [109]. Compound 145 effectively activated the insulin 
signaling pathway, greatly promoted glucose uptake in 3T3-L1 cells, and showed strong 
insulin-sensitizing activities. The potential targets of action for dysidine were probed, and the results 
indicated that dysidine exhibited its cellular effects through activation of the insulin pathway, possibly 
through the inhibition of protein tyrosine phosphatases, with more specific inhibition against protein 
tyrosine phosphatase 1B (PTP1B) [110]. 3′-Aminoavarone (146), and 3′-phenethylaminoavarone (147), 
have been isolated from the marine sponge Dysidea sp. collected in Papua New Guinea along with 
avinosol (148), which is the first example of a naturally occurring meroterpenoid-nucleoside conjugate. 
Avinosol
 
showed antiinvasion activity in a cell-based assay [111]. The structures of popolohuanones 
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A–F (148–154), isolated from different species of the genus Dysidea [66,112–114], are formed by two 
subunits. Popolohuanone A (149) and popolohuanone F (154) showed DPPH radical scavenging 
activity, with an IC50 value of 35 μM [114]. Popolohuanone E (153) was revealed as a potent 
topoisomerase II inhibitor with selective cytotoxicity against the A549 non-small cell human lung 
cancer cell line [113] (Figure 12). 
Figure 12. Amino- and amino acid- substituted quinone containing meroterpenes. 
 
Nakijiquinones A–R (155–172) and nakijinol (173) (Figure 13) constitute a large class of 
sesquiterpenequinones of natural origin with an amino acid (nakijiquinones A–D, 155–158) an heterocyclic 
moiety (nakijinol, 173), or an amino acid-derived amino group (nakijiquinones G–R, 161–172) which 
have been isolated from five collections of Okinawan marine sponge of the Family Spongiidae [115–119]. 
Nakijiquinones E (159) and F (160) were the first dimeric sesquiterpeneoids possessing a 
3-aminobenzoate moiety [117]. Nakijiquinones A–D (155–158) showed in vitro cytotoxicity against 
L-1210 (IC50 values between 2.8 and 8.1 μg/mL) and KB (IC50 values between 1.2 and 7.6 μg/mL [115], 
while nakijiquinones G–I (143–145), slightly cytotoxic, and C (141) showed inhibitory activity against 
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protein tyrosine kinase HER2 [116,118]. Studies on the total synthesis and structure-activity relationship 
of nakijiquinones have been performed by Waldmann et al. and it was found that simplified analogs of 
nakijiquinones A–D exhibited inhibitory activities against different kinds of tyrosine kinases [120]. 
Nakijiquinones J–R at 1 mM were tested for inhibitory activities against EGFR and HER2 tyrosine 
kinases. Among them, nakijiquinones P and R exhibited inhibitory activities against EGFR (76 and 
>99% inhibition, respectively), while nakijiquinones N, O and R showed inhibitory activities against 
HER2 (66%, 59% and 52% inhibition, respectively). The HER2/Neu tyrosine kinase receptor is hugely 
overexpressed in about 30% of primary breast, ovary, and gastric carcinomas. Nakijiquinones are the 
only naturally occurring inhibitors of this important oncogene [51,120]. 
Figure 13. Nakijiquinones and nakijinol. 
 
There are some compounds that also have a fourth ring, through an oxygen (most times) or carbon 
bridge between the decalin and the benzo(hydro)quinone ring (Figure 14). Dactyloquinones A and B 
(174 and 175), having a six-membered-ring made by ether linkages between C-10 and C-17 of 
ilimaquinone and 5-epi-ilimaquinone, respectively [121], dactyloquinones D and E (176 and 177), both 
possessing a six membered-ring made from ether linkages between C-8 and C-17 of of ilimaquinone and 
5-epi-ilimaquinone, respectively [122], have been isolated from a collection of Dactylospongia elegans 
at Okinawa (Japan). An oxygen bridge between the benzo(hydro)quinone moiety linked at C-11 and C-8 
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or C-10 to form dihydropyran rings has been also observed in aureol (178) [123], strongylin (179) [124], 
smenoqualone (180) [45], cyclospongiaquinone-1 (181) [79,88], dehydrocyclospongiaquinone-1  
(182) [79,88], and ent-chromazonarol (183), isolated from Dysidea pallescens [125], whose structure 
was confirmed by chemical synthesis performed from (−)-scalareol [126]. The epimer of 183, 
8-epichromazonarol (184), was isolated from Smenospongia aurea [123]. Interestingly, 
ent-chromazonarol (183) resulted moderately cytotoxic activity against P-388, A-549. HT-29 and 
MEL-28 cells, while its enantiomer chromazonarol, isolated from a brown alga, was inactive [127]. An 
enantioselective cyclization of 2-(polyprenyl)phenol derivatives to afford polycyclic terpenoids bearing 
a chroman skeleton such as (−)-chromazonarol by a new artificial cyclase has been described [128]. 
Puupehenone (185) possessing a drimane skeleton differs from typical natural sesquiterpene quinones 
by having a quinone–methide system. First isolated by Scheuer and co-workers from the sponge 
tentatively identified as Chondrosia chucalla [129], 185 has so far been isolated from different sponges, 
mainly of orders Verongida and Dictyoceratida, together with many other puupehenone-derived 
congeners (186–192) engendered by the presence of the highly electrophilic quinone–methide system 
and oxygen functionalities [129–137] (Figure 11). The puupehenones display a wide range of biological 
properties as angiogenesis inhibitors [138], antitumor [130,131], antifungal [48,129], antiviral [48], 
antimalarial [130], antituberculosis [139], immunomodulatory [138,140], and antioxidant agents [141]. 
The total synthesis of (+)-puupehenone (185) was achieved in ten steps starting from commercially 
available (+)-sclareolide [142]. 
Structures with a fourth five-membered oxygen spiranic ring are cyclospongiaquinone-2 (193) [79,88], 
its analogs 7,8-dehydrocyclospongiaquinone-2 (194) and 9-epi-7,8-dehydrocyclospongiaquinone-2 
(195) [89], and the corallidyctals A–D (196–199), isolated from the marine sponge Aka (=Siphonodictyon) 
coralliphagum [102,143]. Both corallidictyal A (196) and B (197) inhibit PKC with an IC50 = 28 μM, 
while assays addressing another cAMP-dependent kinase did not afford inhibition at concentrations of 
300 μM, indicating its selectivity. Further, the assays revealed selectivity against the α isoform of  
PKC [102]. Corallidictyals C (198) and D (199) were tested in antiproliferative assays using cultures of 
mouse fibroblasts and activity was linked to the presence of the ortho-hydroquinone moiety [143]. 
Uncommon cyclizations are observed in the aminoquinone cyclosmenospongine (200) [144,145], 
neodactyloquinone (201) [146], and dactyloquinone C (202) [122]; this latter compounds, together 
with bis(sulfato)-cyclosiphonodictyol A (203), isolated from Siphonodictyon coralliphagum, represent 
the only examples with a further seven-membered ring. Compound 203 showed inhibitory activity against 
the binding of [
3
H]-LTB4 to human neutrophils, with IC50 = 44.5 μM [147] (Figure 14). 
Sesquiterpene benzo(hydro)quinones with more unusual and/or complex structures are showed in 
Figure 15. Frondosins A–E (204–208), from Dysidea frondosa, were found to be inhibitors of 
interleukin-8 receptors and protein kinase C in the low micromolar range [148]. 
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Figure 14. Meroterpenoids with a fourth ring originated by an ether linkage between the 
benzo(hydro)quinone and terpene moieties. 
 
Dysidavarones A–D (209–212), isolated from Dysidea avara, possess the unprecedented 
―dysidavarane‖ carbon skeleton. Their cytotoxic activity against four human cancer cell lines, cervix 
(HeLa), lung (A549), breast (MDA231), and hepatoma (QGY7703), were evaluated. In particular, 
Dysidavarones A (209) showed a growth inhibitory effect against HeLa cells with an IC50 value of  
39.9 μM, and dysidavarone D (212) showed inhibitory effects against the four cell lines with IC50 values 
of 28.8, 21.4, 11.6, and 28.1 μM, respectively. In addition, dysidavarones A (209) and D (212) also 
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showed inhibitory activity on protein tyrosine phosphatase PTP1B with IC50 values of 9.98 and 21.6 μM, 
respectively [149]. 
Figure 15. Sesquimeroterpenoids with unusual and/or complex structures. 
 
Investigation of Pacific sponges of the genus Xestospongia, yielded some quinone compounds with 
biological activites, halenaquinone (213) and xestoquinone (214) [150,151]. Both compounds showed 
cardiotonic properties and inhibitory activity against Ca
2+
 ATPase, phosphatidylinositol 3-kinase, 
Mar. Drugs 2013, 11 1620 
 
 
protein-tyrosine kinase, and mammalian topoisomerase I. In addition, halenaquinone (213) showed 
cytotoxic activity against KB and P388 cell lines and it inhibited recombinant human Cdc25B in vitro 
with IC50 values of 0.7 μM [152,153]. From an Adocia sp. sponge from Truk Lagoon were isolated 
adociaquinones A (215) and B (216) [154]. They exihibited a cytotoxic activity toward P388, HCT, 
KB16, and HEP-3B cell lines. Moreover, compound 216 inhibited recombinant human Cdc25B in vitro 
with IC50 values of 0.07 μM [152]. 
Alisiaquinones A–C (217–219) and alisaquinol (220) [155], isolated from a New Caledonian deep 
water sponge, are related to xestoquinone,
 
halenaquinone, adociaquinones, but they show an unusual 
substitution pattern on the furan ring. These new meroterpenes displayed mild activity with micromolar 
range on two enzymatic targets of importance for the control of malaria, the plasmodial kinase Pfnek-1 
and a protein farnesyl transferase (PFT) as well as on different chloroquine-sensitive and 
chloroquine-resistant strains of Plasmodium falciparum [155]. 
Particularly, alisiaquinone C (215), bearing the taurine substituent, displayed a submicromolar 
activity on P. falciparum and a competitive selectivity index on the different plasmodial strains, 
especially on the chloroquine-resistant strain PfFcMC29. For alisiaquinones A (217) and C (219), the  
in vivo activity was also investigated, but they displayed a relatively high level of toxicity. Bispuupehenone 
(221), dipuupehedione (222), and diplopuupehenone (223) are dimeric molecules isolated from Dysidea sp. 
and Hyrtios sp. [131,137,141]. The unsymmetrical structure of diplopuupehenone comprises 
puupehenone and puupehenol segments. Bioactivity assays of these compounds unveiled the cytotoxic 
activity of dipuupehedione (222) against KB cells (ED50 = 3 μg/mL) [131] and the antioxidant properties 
of diplopuupehenone (223). Compound 223 exhibited the greatest potency in scavenging the 
2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical with an IC50 value of 8 μM, in comparison with that 
of puupehenone (185, IC50 32 μM), bispuupehenone (221), IC50 120 μM) and the standard antioxidant 
Trolox (IC50 16 μM) [131]. 
The meroterpene sulfate fascioquinol E (224), isolated from a Fasciospongia sp., (Figure 16) is a rare 
example of diterpene benzo(hydro)quinone with a linear terpene moiety [156]. Fascioquinol E is an 
inhibitor of protein tyrosine phosphatase CpsB, which unexpectedly inhibited the growth of 
Gram-positive pathogens. CpsB is a member of the polymerase and histidinol phosphate phosphatase 
(PHP) domain family. Another member of this family found in a variety of Gram-positive pathogens is 
DNA polymerase PolC and this competes away fascioquinol E inhibition of CpsB phosphatase activity. 
It was showed that fascioquinol E not only inhibits the phosphatase activity of CpsB, but also ability of 
PolCPHP to catalyse the hydrolysis of pNP-TMP. This suggests that PolC may be the essential target of 
fascioquinol E, and that the PHP domain may represent an as yet untapped target for the development of 
novel antibiotics [157,158]. 
Cacospongins B–D (225–227), from Cacospongia sp. and jaspaquinol (228) from the sponges  
Jaspis splendens and Suberea sp. [159,160] exhibit a monocyclic terpene portion. Compounds 227 and 
228 showed significant antimicrobial activity against S. epidermidis (MIC = 20 and 5.0 μg/mL, 
respectively) though weaker in comparison with vancomycin [161,162] (MIC = 0.625 μg/mL). 
Compound 228 showed also to be active as human 15-lipoxygenase and 12-lipoxygenase inhibitor with 
IC50 = 0.3 ± 0.1 μM and IC50 = 4.5 ± 1.0 μM, respectively [163]. 
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Figure 16. Diterpene benzo(hydro)quinones with linear or monocyclic terpene moieties. 
 
From extracts of two different sponges, Jaspis splendens (order Choristida, family Jaspidae) and 
Suberea sp. (order Verongida, family Aplysinellidae), collected in Papua New Guinea, mixed biogenesis 
bicyclic diterpene-benzenoid compounds, (−)-jaspic (229) and (−)-subersic (230) acids have been 
isolated (Figure 17) [163]. Both compounds 229 and 230 were active as human 15-lipoxygenase 
(15-hLO) inhibitors (IC50 values between 0.3 and 15.0 μM) and 229 was also shown to inhibit 
12-lipoxygenase (12-hLO) (IC50 = 0.7 ± 0.05). (+)-Isojaspic acid (231) has been isolated from 
Cacospongia sp. and it has shown a significant antimicrobial activity against S. epidermidis  
(MIC = 2.5 μg/mL) [161]. Interestingly, the enantiomer of the (−)-subersic acid (230), the (+)-subersic 
acid (232), isolated from Acanthodendrilla sp., inhibited the protein kinase MK2 with IC50 of  
9.6 μM [164]. 
Figure 17. Diterpene benzo(hydro)quinones with bicyclic terpene moieties. 
 
Chromane meroditerpenes (Figure 18) have been isolated from Psammocinia and Fasciospongia sp. 
Bioassay-guided fractionation of the active Psammocinia extract led to the isolation of a series of hLO 
inhibitory chromanes meroditerpenes named chromarols A–E (233–237) [165]. These compounds were 
tested in order to determine their comparative inhibition against 15-hLO and 12-hLO. The results of this 
analysis were quite remarkable, with chromarols A–D (233–236) exhibiting selective (>25–166-fold) 
inhibition against 15-hLO versus 12-hLO. Furthermore, 233–236 were relatively potent inhibitors of 
15-hLO, exhibiting IC50 values ranging from 0.6 ± 0.1 to 4.0 ± 0.5 μM. In stark contrast, the 
6-carboxychromane derivative, chromarol E (237), exhibited no selectivity for either isozyme. Instead, 
237 displayed comparable potency against both 15-hLO and 12-hLO (IC50 = 3.3 ± 0.4 and 1.2 ± 0.1 μM, 
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respectively). A new metabolite, fascioquinol F (238), with a structure comparable to those of 
chromarols, has been isolated from Fasciospongia sp. [156]. 
Figure 18. Chromane meroditerpenes. 
 
The screen of marine sponges Acanthodendrilla sp. and Fasciospongia sp. led to isolation of 
diterpene benzo(hydro)quinones with tricyclic terpene moieties (Figure 19). The extract of 
Acanthodendrilla sp., collected in Indonesia, led to the isolation of (+)-makassaric acid (239) which also 
is an inhibitor of the protein kinase MK2 with an IC50’s value of 20 μM [164]. Chemical investigation of 
a southern Australian deep-water marine sponge, Fasciospongia sp., returned the new meroterpene 
sulfate fascioquinol A (240) together with its desulfated analog, fascioquinol B (241). Both compounds 
240 and 241 displayed a promising Gram-positive selective antibacterial activity towards 
Staphylococcus aureus (IC50 0.9–2.5 μM) and Bacillus subtilis (IC50 0.3–7.0 μM) [156]. 
Figure 19. Diterpene benzo(hydro)quinones with tricyclic terpene moieties. 
 
Meroditerpenoids with more complex structures featuring further oxygen spiranic or dihydropyranic 
rings, are strongylophorines (242–262) (Figure 20), first reported from the sponge Strongylophora durissima 
collected in Papua New Guinea [166] and in the Philippines [167]. Strongylophorines exhibited several 
biological activities including antimicrobic and insecticidal activities, lethal toxicity to brine shrimp, and 
inhibition of the maturation of starfish oocytes [168–172]. Strongylophorines-8 (247) and -26 (262) 
were found to have potent antiinvasive activity using MDA-MB-231 breast cancer cells [173], whereas 
the strongylophorines 2 (243), 3 (244), and 8 (247) inhibited the HIF-1-dependent luciferase expression 
in U251-HRE cells with EC50 values much lower than their cytotoxic concentrations [174].
 
In addition, 
further studies have shown that strongylophorine-8 (247) activated the Nrf2/ARE pathway and protected 
neuronal cells against oxidative stress, representing the first example of a neuroprotective 
pro-electrophilic compound from marine organisms [175]. Related to strongylophorines are 
fascioquinols C (263) and D (264), isolated from Fasciospongia sp. [156]. 
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Figure 20. Strongylophorines and fascioquinols C and D. 
 
Coscinoquinol (265), its isomer 266, and the related sulfate-containing compounds halisulfates and 
coscinosulfates (267–271) (Figure 21) are examples of sestermeroterpenes [176–179]. Halisulfates and 
coscinoquinols have been reported to possess diverse bioactivities: cytotoxicity, antimicrobial activity, 
and inhibitory activities against isocitrate lyase, phospholipase A2, serine protease, phosphatase, and 
PMA-induced inflammation [177–183]. Significant structure-activity relationships have been evidenced 
in this compounds family. Compounds 265, 267 and 269 were active (MIC 1.56–25 μg/mL) against 
Gram-positive (Bacillus subtilis, Micrococcus luteus, and Staphylococcus aureus) and/or -negative 
(Proteus vulgaris and Salmonella typhimurium) bacteria. Interestingly, despite the significant inhibition 
shown by halisulfate 1 (267), its isomer 268 displayed no antibacterial activity at all. This same 
phenomenon was observed between coscinoquinol (265) and its isomer (266). Coscinoquinols (265 and 
266) were also cytotoxic against the K562 cell line, showing more potent inhibition than doxorubicin, 
while the halisulfates with hydroquinone moiety (267–269) were inactive. In enzyme-based assays, 
compounds 267–269, exhibited significant inhibition of sortase A, a key enzyme for the cell adhesion of 
Gram-positive bacteria; this activity was related to the presence of both hydroquinone and sulfate 
functionalities. In an assay against Candida albicans-derived isocitrate lyase (ICL), an enzyme of the 
glyoxylate cycle in microorganisms, the coscinoquinols were inactive, while all other sulfate-containing 
compounds displayed moderate to significant inhibition. A similar trend was observed for the 
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Na+/K+-ATPase inhibitory assay, in which more potent activities were found for the sulfate-containing 
compounds (267–268) than the coscinoquinols (265 and 266) [176]. Coscinosulfate (270) displayed 
significant inhibitory activity towards CDC25A phosphatase with an IC50 of 3 μM, while its analog 
(271) was less active (IC50 value of 18 μM) [184]. Both compounds 270 and 271 showed also an 
antimicrobial activity towards S. aureus with inhibition zones, respectively: 12 mm (50 μg/disk) and  
10 mm (100 μg/disk) [179]. 
Figure 21. Sestermeroterpenes: coscinoquinols, coscinosulfates, and halisulfates. 
 
Examples of hexaprenoid hydroquinones are reported in Figure 22. The sulfated compounds toxiusol 
(272), shaagrockol B (273), shaagrockol C (274), toxicol A (275), toxicol B (276), the p-hydroquinone 
derivative of compound 275, and toxicol C (277), isolated from Toxiclona toxius [185,186], are of 
interest not only because of their structures but also because of their biological properties, which 
includes an important activity against human immunodeficiency virus type 1 (HIV-1) reverse 
transcriptase (RT). The hydrolysis of compounds 272 and 274 yielded the corresponding hydroquinones 
designated as compounds 278 and 279, and further oxidation of compound 276 afforded the 
corresponding p-quinone derivative. Compounds 272–276, 278 and 279 exhibited inhibitory activity of 
both DNA polymerizing functions of HIV-1 RT but failed to inhibit the RT-associated ribonuclease H 
activity [74]. The sponges of the genus Adocia (order Haplosclerida, family Chalinidae), collected in 
different places, also are the source of biologically active hexaprenoid hydroquinone sulfates  
(Figure 22) [187–191]. From the crude extract of Haliclona (aka Adocia) sp., collected at Palau, it has 
been possible to isolate adociasulfates 1–6 (280–285) [187], which contain mono- or di-sulfated 
hydroquinones, and adociasulfate 10 (286) (Figure 22) [188], in which there is an unusual glycolic acid 
residue in place of one of the sulfates groups. These compounds are inhibitor of the kinesin family of 
microtubule proteins, a group of proteins that transport cargo along the microtubules within the  
cells [192,193]. Adociasulfate 10 (286) had an IC50 of 7 μM, which is almost identical to the activity of 
adociasulfate 2 (281), IC50 of 6 μM. It is interesting to note that substitution of one sulfate group by the 
glycolic acid moiety of adociasulfate 10 (286) does not significantly reduce its inhibition of kinesin 
motors. Independently, adociasulfates 1 (280), 7 (287), and 8 (288), isolated from an unidentified 
species of Adocia collected in Northern Queensland, were found to have H
+
-ATPase protein pump 
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activity [189]. A further investigation of a Palauan specimen of Haliclona led to the isolation of three 
new merotriterpenoids, adociaquinol (289), adociasulfates 11 (290) and 12 (291) [190], whereas an 
investigation of a sample of Adocia aculeata collected from Cormorant Pass, North Great Barrier Reef, 
led to the isolation of a new triterpene hydroquinone sulfate, adociasulfate 9 (292) [191]. Two new 
terpene-ketides, haliclotriol A (293) and haliclotriol B (294), have been isolated from two Indo-Pacific 
members of Aciona genus [194]. The major structure of haliclotriols A (293) and B (294) is derived from 
the cyclization of a hexaprenoid precursor. The biological activity properties of the triterpenes were 
investigated: a weak antimicrobial activity was observed for haliclotriol B (294) at 1 mg disk against  
B. subtilis and S. aureus, respectively. 
Figure 22. Sulfated triterpene hydroquinones. 
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Halioxepine (295), from an Indonesian sample of Haliclona sp. [195] showed moderate cytotoxicity 
against NBT-T2 cells with IC50 4.8 μg/mL and it also exhibited antioxidant activity against 
1,1-diphenyl-2-picrylhydrazyl (DPPH) with IC50 3.2 μg/mL as well as other hydroquinone-containing 
meroditerpenes [196]. Halicloic acids A (296) and B (297), isolated from a sample of Haliclona 
collected in the Philippines [197], are related to the known compounds adociasulphates 2 (281) [187] 
and 10 (286) [188] and haliclotriol A (293) [194]. Bioassay-guided fractionation of the extract identified 
halicloic acids A (296) and B (297) as indoleamine 2,3-dioxygenase inhibitors. Akaterpin (298), isolated 
from the marine sponge Callyspongia sp. having disulfated hydroquinone moiety, is an inhibitor of 
phosphatidylinositol-specific phospholipase C with an IC50 value of 0.5 μg/mL. It also inhibits neutral 
sphingomyelinase weakly with an IC50 of 30 μg/mL [198]. Three new disulfated meroterpenoids, 
ilhabelanol (299), ilhabrene (300), both with unprecedented meroterpenoid carbon skeletons, and 
isoakaterpin (301), have been isolated from extracts of the same sponge (Figure 22). They are inhibitors 
of Leishmania spp. adenosine phosphoribosyl transferase (APRT), an important component of the 
purine salvage pathway in the parasites [199]. 
4. Meroterpenes from Soft Corals 
A limited number of meroterpenoids have been isolated from soft corals, the only examples being 
the geranyl idroquinone derivatives 302–304 isolated from the marine octocoral Alcyonium fauri [200] 
and the meroditerpenois 305–314 isolated from Nephthea chabrolii [201–203] (Figure 23). 
Figure 23. Meroterpenoids from soft corals. 
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In a NCI’s CEM-SS cell line screen, designed to detect agents acting at any stage in the HIV virus 
reproductive cycle, rietone (302) showed moderate activity (EC50 1.23 μM and IC50 9.32 μM) [200].  
N. chabrolii metabolites series include the naphthoquinone derivatives chabrolonaphthoquinone A–C 
(305–307), the tetraprenyltoluquinol-related metabolites chabrolohydroxybenzoquinones A–G (308–314), 
and the tetraprenyltoluquinones chabrolobenzoquinones A–H (315–322). Compound 306 exhibited 
significant cytotoxicity against the growth of the MDA-MB-231 (IC50 4.7 μM) cancer cell line and 
moderate to weak cytotoxicity against Hep G2 (IC50 12.4 μM) and A549 (IC50 33.9 μM) cancer cell 
lines, respectively. Also, metabolites 307 and 314 exhibited moderate to weak cytotoxicity toward these 
cancer cells. Other metabolites either were inactive or exhibit only weak cytotoxicity against the growth 
of the above three cancer cell lines. 
5. Conclusive Remarks 
The great chemical diversity generating in the group of meroterpenes isolated from marine 
invertebrates and their wide range of biological activities represent a useful tool for development of new 
therapeutics. But the biomedical potential of these compounds could be greatly enhanced by a 
comprehensive understanding of their biosynthetic origin combined with the recent progress in 
molecular biology. The occurrence of different but biosynthetically related meroterpenes in different 
organisms, in terrestrial sources, and/or in collections of the same organism from distinct geographical 
locations, strongly supports the possibility of their biosynthesis by associated microorganisms. 
Significantly, several meroterpenoids have been recently isolated from Aspergillus spp. derived from 
tissues of marine invertebrates. It is known that members of the genus Aspergillus can combine 
polyketide and terpene precursors to produce meroterpenoids, some of whom having important 
relevance to human health; this is the case of territrem B, produced by A. terreus, a potent irreversible 
inhibitor of acetyl cholinesterase (AChE) and a candidate for drug development for treating Alzheimer’s 
disease [204]. Examples of meroterpenoids isolated from invertebrate-associated Aspergillus spp. are 
tropolactones A–D (323–326) isolated from an Aspergillus sp. derived from an unidentified  
sponge [205], insuetolides A–C (327–329) from A. insuetus isolated from the Mediterranean sponge 
Psammocinia sp. [206], terretonins E (330) and F (331), isolated from A. insuetus derived from the 
Mediterranean sponge Petrosia ficiformis [207], austalides M–Q (332–336) from an Aspergillus sp. 
derived from the sponge Tethya aurantium [208], and yanuthones (337–344) isolated from A.niger 
obtained from tissue homogenates of an Aplidium ascidian [209] (Figure 24). Thus, there are grounds to 
suppose that meroterpenoids isolated from marine invertebrates or, at least, portions of their structure are 
microbial products, most likely elaborated by Aspergillus fungi. If confirmed, this possibility could work 
to advantage the research on these compounds, both for the exploitation of their huge chemical diversity 
and for a potential large-scale production of the bioactive molecules. The Aspergillus genus of fungi, 
indeed, has been largely investigated due to its medical and commercial importance. Research on 
Aspergillus has contributed much knowledge about its fundamental cell biology and biochemistry and, 
foremost, the significance of Aspergillus was cause for the sequencing of the genomes of some of the 
most well-known members of this genus which are now publicly available [210]. Attempts to locate the 
biosynthetic genes for meroterpenoids production in the genome of some Aspergillus spp. have been 
performed with encouraging results; the biosynthetic pathway for some meroterpenoids (austinol, 
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terretonin) has been proposed [211,212]. Understanding of Aspergillus secondary metabolism would 
greatly profit from the genome sequencing projects; sequence information greatly facilitates the 
identification of natural product genes, the function of which can be demonstrated by molecular 
biological and biochemical approaches. When a set of genes involved in the formation of the same 
secondary metabolite are recognized, a biosynthesis can be proposed. Down the road, such advances 
should be useful for enhanced production of secondary metabolites of interest and the development of 
second-generation compounds with improved pharmacodynamic and pharmacokinetic characteristics. 
Thus, advances in Aspergillus secondary metabolite research in the post-genomic era will bring an 
understanding of meroterpenoids biosynthesis at the genetic level which should facilitate engineering of 
second generation molecules and increasing production of first generation compounds. 
Figure 24. Meroterpenoids from marine invertebrates-associated Aspergillus spp. 
 
Mar. Drugs 2013, 11 1629 
 
 
Acknowledgments 
This work was supported by the European Commission through the FP7 Projects no. 229893 
(NatPharma) and 311848 (BlueGenics), and by the Italian Ministero dell’Università e della Ricerca 
(MIUR) (PRIN2009: Sostanze naturali ed analoghi sintetici in grado di interferire con target biologici 
coinvolti nel controllo della crescita tumorale). 
Conflict of Interest 
The authors declare no conflict of interest. 
References 
1. Thomson, R.H. Naturally Occurring Quinones, 2nd ed.; Academic Press: London, UK, 1971;  
pp. 93–197. 
2. Pennock, J.F. Terpenoids in Plants; Pridham, J.B., Ed.; Academic Press: London, UK, 1967;  
pp. 129–146. 
3. Monks, T.J.; Hanzlik, R.P.; Cohen, G.M.; Ross, D.; Graham, D.G. Quinone chemistry and toxicity. 
Toxicol. Appl. Pharmacol. 1992, 112, 2–16.  
4. O’Brien, P.J. Molecular mechanisms of quinone cytotoxicity. Chem. Biol. Interact. 1991, 80, 
1–41. 
5. Zubìa, E.; Ortega, M.; Salvà, J. Natural products chemistry in marine ascidians of the genus 
Aplidium. Mini Rev. Org. Chem. 2005, 2, 546–564. 
6. Menna, M.; Fattorusso, E.; Imperatore, C. Alkaloids from marine ascidians. Molecules 2011, 16, 
8694–8732. 
7. Menna, M.; Aiello, A. The Chemistry of Marine Tunicates. In Handbook of Marine Natural 
Products; Fattorusso, E., Gerwick, W.H., Taglialatela-Scafati, O., Eds.; Springer Science + Business 
Media: New York, NY, USA, 2012; Volume 1, pp. 295–385. 
8. Fenical, W. Geranyl hydroquinone, a cancer-protective agent from the tunicate Aplidium species. 
Food Drugs Sea Proc. 1976, 4, 388–394. 
9. Sato, A.; Shindo, T.; Kasanuki, N.; Hasegawa, K. Antioxidant metabolites from the tunicate 
Amaroucium multiplicatum. J. Nat. Prod. 1989, 52, 975–981. 
10. Aknin, M.; Dayan, T.L.A.; Rudi, A.; Kashman, Y.; Gaydou, E.M. Hydroquinone antioxidants 
from the Indian Ocean tunicate Aplidium savignyi. J. Agric. Food Chem. 1999, 47, 4175–4177. 
11. Garrido, L.; Zubía, E.; Ortega, M.J.; Salvá, J. New meroterpenoids from the ascidian  
Aplidium conicum. J. Nat. Prod. 2002, 65, 1328–1331. 
12. Shubina, L.K.; Fedorov, S.N.; Radchenko, O.S.; Balaneva, N.N.; Kolesnikova, S.A.;  
Dmitrenok, P.S.; Bode, A.; Dong, Z.; Stonik, V.A. Desmethylubiquinone Q2 from the far-eastern 
ascidian Aplidium glabrum: Structure and synthesis. Tetrahedron Lett. 2005, 46, 559–562. 
13. Chan, S.T.S.; Pearce, A.N.; Januario, A.H.; Page, M.J.; Kaiser, M.; McLaughlin, R.J.;  
Harper, J.L.; Webb, V.L.; Barker, D.; Copp, B.R. Anti-inflammatory and antimalarial 
meroterpenoids from the New Zealand ascidian Aplidium scabellum. J. Org. Chem. 2011, 76, 
9151−9156. 
Mar. Drugs 2013, 11 1630 
 
 
14. Guella, G.; Mancini, I.; Pietra, F. Verapliquinones: Novel diprenylquinones from an Aplidium sp. 
(Ascidiacea) of Ile-Verte waters, Brittany. Helv. Chim. Acta 1987, 70, 621–626. 
15. Appleton, D.R.; Chuen, C.S.; Berridge, M.V.; Webb, V.L.; Copp, B.R. Rossinones A and B, 
biologically active meroterpenoids from the Antarctic ascidian, Aplidium species. J. Org. Chem. 
2009, 74, 9195–9198. 
16. Howard, B.M.; Clarkson, K. Simple prenylated hydroquinone derivatives from the marine 
urochordate Aplidium californicum natural anticancer and antimutagenic agents. Tetrahedron Lett. 
1979, 46, 4449–4452. 
17. Fedorov, S.N.; Radchenko, O.S.; Shubina, L.K.; Balaneva, N.N.; Bode, A.M.; Stonik, V.A.;  
Dong, Z. Evaluation of cancer-preventive activity and structure-activity relationship of 
3-demethylubiquinone Q2, isolated from the ascidian Aplidium glabrum and its synthetic analogs. 
Pharm. Res. 2006, 23, 70–81. 
18. Fedorov, S.N.; Radchenko, O.S.; Shubina, L.K.; Balaneva, N.N.; Agafonova, I.G.; Bode, A.M.; 
Jin, J.O.; Kwak, J.Y.; Dong, Z.; Stonik, V. Anticancer activity of 3-demethylubiquinone Q2.  
In vivo experiments and probable mechanism of action. Anticancer Res. 2008, 28, 927–932. 
19. Laird, D.W.; Poole, R.; Wikstroem, M.; van Altena, I.A. Pycnanthuquinone C, an unusual 
6,6,5-tricyclic geranyltoluquinone from the western australian brown alga Cystophora harveyi.  
J. Nat. Prod. 2007, 70, 671–674. 
20. Lumb, J.P.; Trauner, D. Pericyclic reactions of prenylated naphthoquinones: Biomimetic 
syntheses of mollugin and microphyllaquinone. Org. Lett. 2005, 7, 5865–5868. 
21. Morimoto, S.; Komatsu, K.; Taura, F.; Shoyama, Y. Purification and characterization of 
cannabichromenic acid synthase from Cannabis sativa. Phytochemistry 1998, 49, 1525−1529. 
22. Simon-Levert, A.; Arrault, A.; Bontemps-Subielos, N.; Canal, C.; Banaigs, B. Meroterpenes from 
the ascidian Aplidium aff. densum. J. Nat. Prod. 2005, 68, 1412–1415. 
23. Simon-Levert, A.; Aze, A.; Bontemps-Subielos, N.; Banaigs, B.; Genevière, A.M. Antimitotic 
activity of methoxyconidiol, a meroterpene isolated from an ascidian. Chem. Biol. Interact. 2007, 
168, 106–116. 
24. Targett, N.M.; Keeran, W.S. A terpenehydroquinone from the marine ascidian  
Aplidium constellatum. J. Nat. Prod. 1984, 47, 556–557. 
25. Rochfort, S.J.; Metzger, R.; Hobbs, L.; Capon, R.J. New chromenols from a southern Australian 
tunicate Aplidium solidum. Aust. J. Chem. 1996, 49, 1217–1219.  
26. Carrol, A.R.; Bowden, B.F.; Coll, J.C. Studies of Australian ascidians. III. A new 
tetrahydrocannabinol derivative from the ascidian Synoicum costellatum. Aust. J. Chem. 1993, 46, 
1079–1083. 
27. Choi, H.; Hwang, H.; Chin, J.; Kim, E.; Lee, J.; Nam, S.J.; Lee, B.C.; Rho, B.J.; Kang, H. 
Tuberatolides, potent FXR antagonists from the korean marine tunicate Botryllus tuberatus.  
J. Nat. Prod. 2011, 74, 90–94. 
28. Davis, R.A.; Carroll, A.R.; Quinn, R.J. Longithorols C–E. Three new macrocyclic sesquiterpene 
hydroquinone metabolites from the Australian ascidian Aplidium longithorax. J. Nat. Prod. 1999, 
62, 1405–1409. 
Mar. Drugs 2013, 11 1631 
 
 
29. Carbone, M.; Nunez-Pons, L.; Paone, M.; Castelluccio, F.; Avila, C.; Gavagnin, M. 
Rossinone-related meroterpenes from the Antarctic ascidian Aplidium fuegiense. Tetrahedron 
2012, 68, 3541–3544. 
30. Fort, D.M.; Ubillas, R.P.; Mendez, C.D.; Jolad, S.D.; Inman, W.D.; Carney, J.R.; Chen, J.L.; 
Ianiro, T.T.; Hasbun, C.; Bruening, R.C.; et al. Novel antihyperglycemic terpenoid-quinones from 
Pycnanthus angolensis. J. Org. Chem. 2000, 65, 6534–6539. 
31. Zhang, Z.; Chen, J.; Yang, Z.; Tang, Y. Rapid biomimetic total synthesis of (±)-rossinone B.  
Org. Lett. 2010, 12, 5554–5557. 
32. Fu, X.; Hossain, M.B.; van der Helm, D.; Schmitz, F.J. Longithorone A: Unprecedented dimeric 
prenylated quinone from the Tunicate Aplidium longithorax. J. Am. Chem. Soc. 1994, 116, 
12125–12126. 
33. Fu, X.; Hossain, M.B.; Schmitz, F.J.; van der Helm, D. Longithorones, unique prenylated  
para- and metacyclophane type quinones from the Tunicate Aplidium longithorax. J. Org. Chem. 
1997, 62, 3810–3819. 
34. Davis, R.A.; Carroll, A.R.; Quinn, R.J. Longithorones J and K, two new cyclofarnesylated quinone 
derived metabolites from the Australian ascidian Aplidium longithorax. J. Nat. Prod. 1999, 62, 
158–160. 
35. Fu, X.; Ferreira, M.L.G.; Schmitz, F.J. Longithorols A and B, novel prenylated  
paracyclophane- and metacyclophane-tipe hydroquinones from the Tunicate Aplidium longithorax. 
J. Nat. Prod. 1999, 62, 1306–1310. 
36. Kotha, S.; Shirbhate, M.E. Diversity-oriented approach to macrocyclic cyclophane derivatives via 
ring-closing metathesis. Synlett 2012, 23, 2183–2188. 
37. Issa, H.H.; Tanaka, J.; Rachmat, R.; Higa, T. Floresolides, new metacyclophane hydroquinone 
lactones from an ascidian, Aplidium sp. Tetrahedron Lett. 2003, 44, 1243–1245. 
38. Layton, M.E.; Morales, C.A.; Shair, M.D. Biomimetic synthesis of (−)-longithorone A. J. Am. 
Chem. Soc. 2002, 124, 773–775. 
39. Aiello, A.; Fattorusso, E.; Luciano, P.; Menna, M.; Esposito, G.; Iuvone, T.; Pala, D. 
Conicaquinones A and B, two novel cytotoxic terpene quinones from the Mediterranean ascidian 
Aplidium conicum. Eur. J. Org. Chem. 2003, 2003, 898–900. 
40. Aiello, A.; Fattorusso, E.; Luciano, P.; Mangoni, A.; Menna, M. Isolation and structure 
determination of aplidinones A–C from the Mediterranean ascidian Aplidium conicum: A 
successful regiochemistry assignment by quantum mechanical 13C NMR chemical shift 
Calculations. Eur. J. Org. Chem. 2005, 2005, 5024–5030. 
41. Aiello, A.; Fattorusso, E.; Luciano, P.; Macho, A.; Menna, M.; Muñoz, E. Antitumor effects of two 
novel naturally occurring terpene quinones isolated from the Mediterranean ascidian  
Aplidium conicum. J. Med. Chem. 2005, 48, 3410–3416. 
42. Carbone, A.; Lucas, C.L.; Moody, C.J. Biomimetic synthesis of the apoptosis-inducing 
thiazinoquinone thiaplidiaquinone A. J. Org. Chem. 2012, 77, 9179−9189. 
43. Khalil, I.M.; Barker, D.; Copp, B.R. Biomimetic synthesis of thiaplidiaquinones A and B. J. Nat. 
Prod. 2012, 75, 2256−2260. 
Mar. Drugs 2013, 11 1632 
 
 
44. Aiello, A.; Fattorusso, E.; Luciano, P.; Menna, M.; Calzado, M.A.; Muñoz, E.; Bonadies, F.; 
Guiso, M.; Sanasi. M.F.; Cocco, G.; et al. Synthesis of structurally simplified analogues of 
aplidinone A, a pro-apoptotic marine thiazinoquinone. Bioorg. Med. Chem. 2010, 18, 719–727. 
45. De Rosa, S.; de Giulio, A.; Iodice, C. Biological effects of prenylated hydroquinones: 
Structure-activity relationship studies in antimicrobial, brine shrimp, and fish lethality assays.  
J. Nat. Prod. 1994, 57, 1711–1716. 
46. Muller, W.E.G.; Maidhof, A.; Zahn, R.K.; Schroder, H.C.; Gasic, M.J.; Heidemann, D.;  
Bernd, A.; Kurelec, B.; Eich, E.; Seibert, G. Potent antileukemic activity of the novel cytostatic 
agent avarone and its analogs in vitro and in vivo. Cancer Res. 1985, 45, 4822–4826. 
47. Kondracki, M.L.; Guyot, M. Biologically active quinone and hydroquinone sesquiterpenoids from 
the sponge Smenospongia sp. Tetrahedron 1989, 45, 1995–2004. 
48. Hamann, M.T.; Scheuer, P.J.; Kelly-Borges, M. Biogenetically diverse, bioactive constituents of a 
sponge, order Verongida: Bromotyramines and sesquiterpene-shikimate derived metabolites.  
J. Org. Chem. 1993, 58, 6565–6569. 
49. Alvi, K.A.; Diaz, M.C.; Crews, P.; Slate, D.L.; Lee, R.H.; Moretti, R. Evaluation of new 
sesquiterpene quinones from two Dysidea sponge species as inhibitors of protein tyrosine kinase. 
J. Org. Chem. 1992, 57, 6604–6607. 
50. Loya, S.; Tal, R.; Kashman, Y.; Hizi, A. Illimaquinone, a selective inhibitor of the RNase H 
activity of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents 
Chemother. 1990, 34, 2009–2012. 
51. Gordaliza, M. Cytotoxic terpene quinones from marine sponges. Mar. Drugs 2010, 8, 2849–2870.  
52. Benites, J.; Valderrama, J.A.; Rivera, F.; Rojo, L.; Campos, N.; Pedro, M.; Nascimento, M.S.J. 
Studies on quinones. Part 42: Synthesis of furylquinone and hydroquinones with antiproliferative 
activity against human tumor cell lines. Bioorg. Med. Chem. 2008, 16, 862–868 and all  
previous parts. 
53. Ishibashi, M.; Ohizumi, Y.; Cheng, J.-F.; Nakamura, H.; Hirata, Y.; Sasaki, T.; Kobayashi, J. 
Metachromins A and B, Novel antineoplastic sesquiterpenoids from the okinawan sponge 
Hippospongia cf. metachromia. J. Org. Chem. 1988, 53, 2855–2858. 
54. Kobayashi, J.; Murayama, T.; Ohizumi, Y.; Ohta, T.; Nozoe, S.; Sasaki, T. Metachromin C, a new 
cytotoxic sesquiterpenoid from the okinawan marine sponge Hippospongia metachromia. J. Nat. 
Prod. 1989, 52, 1173–1176. 
55. Kobayashi, J.; Naitoh, N.; Sasaki, T.; Shigemori, H. Metachromins D–H, new cytotoxic 
sesquiterpenoids from the okinawan marine sponge Hippospongia metachromia. J. Org. Chem. 
1992, 57, 5773–5776. 
56. Takahashi, Y.; Kubota, T.; Fromont, J.; Kobayashi, J. Metachromins L–Q, new sesquiterpenoid 
quinones with an aminoacid residue from sponge Spongia sp. Tetrahedron 2007, 63, 8770–8773. 
57. Takahashi, Y.; Yamada, M.; Kubota, T.; Fromont, J.; Kobayashi, J. Metachromins R–T, new 
sesquiterpenoids from marine sponge Spongia sp. Chem. Pharm. Bull. 2007, 55, 1731–1733. 
58. Ovenden, S.P.B.; Nielson, J.L.; Liptrot, C.H.; Willis, R.H.; Tapiolas, D.M.; Wright, A.D.;  
Motti, C.A. Metachromins U–W: Cytotoxic merosesquiterpenoids from an Australian specimen of 
the sponge Thorecta reticulata. J. Nat. Prod. 2011, 74, 1335–1338. 
Mar. Drugs 2013, 11 1633 
 
 
59. Minale, L.; Riccio, R.; Sodano, G. Avarol, a novel sesquiterpenoid hydroquinone with a 
rearranged drimane skeleton from the sponge Disidea avara. Tetrahedron Lett. 1974, 38, 
3401–3404. 
60. Cimino, G.; de Rosa, S.; de Stefano, S.; Cariello, L.; Zanetti, L. Structure of two biologically active 
sesquiterpenoid amino-quinones from the marine sponge Dysidea avara. Experientia 1982, 38, 896. 
61. De Rosa, S.; Minale, L.; Riccio, R.; Sodano, G. The absolute configuration of avarol, a rearranged 
sesquiterpenoid hydroquinone from a marine sponge. J. Chem. Soc. Perkin Trans. 1 1976, 
1408–1414, doi:10.1039/P19760001408. 
62. Giordano, F.; Puliti, R. Structure of the 2,5-dimethyl ether of avarol, a sesquiterpenoid 
hydroquinone from the marine sponge Dysidea avara. Acta Cryst. 1987, C43, 985–988. 
63. Müller, W.E.G.; Sobel, C.; Sachsse, W.; Diehl-Seifert, B.; Zahn, R.K.; Eich, E.; Kljajić, Z.; 
Schröder, H.C. Biphasic and differential effects of the cytostatic agents avarone and avarol on 
DNA metabolism of human and murine T and B lymphocytes. Eur. J. Cancer Clin. Oncol. 1986, 
22, 473–476. 
64. Müller, W.E.G.; Sobel, C.; Diehl-Seifert, B.; Maidhof, A.; Schöder, H.C. Influence of the 
antileukemic and anti-human immunodeficiency virus agent avarol on selected immune responses 
in vitro and in vivo. Biochem. Pharmacol. 1987, 36, 1489–1494. 
65. Cozzolino, R.; de Giulio, A.; de Rosa, S.; Strazzullo, G.; Gašič, M.J.; Sladić, D.; Zlatović, M. 
Biological activities of avarol derivatives, 1. Amino derivatives. J. Nat. Prod. 1990, 53, 699–702. 
66. Sarin, P.S.; Sun, D.; Thornton, A.; Müller, W.E.G. Inhibition of replication of the etiologic  
agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/ 
lymphadenopathy-associated virus) by avarol and avarone. J. Natl. Cancer Inst. 1987, 78, 
663–666. 
67. Schroeder, H.C.; Sarin, P.S.; Rottmann, M.; Wenger, R.; Maidhof, A.; Renneisen, K.;  
Muller, W.E.G. Differential modulation of host cell and HIV gene expression by combinations of 
Avarol and AZT in vitro. Biochem. Pharmacol. 1988, 37, 3947–3952. 
68. Schroeder, H.C.; Wenger, R.; Gerner, H.; Reuter, P.; Kuchino, Y.; Sladic, D.; Muller, W.E.G. 
Suppression of the modulatory effects of the antileukemic and anti-human immunodeficiency 
virus compound avarol on gene expression by tryptophan. Cancer Res. 1989, 49, 2069–2076. 
69. Schatton, W.; Schatton, M.; Pietschmamm, R. Method for the Preparation of Compositions with 
High Avarol Content from Sponge and Use for the Prevention and Treatment of Psoriasis and 
Tumors. Eur. Pat. Appl. EP 1391197 A1, 25 February 2004. 
70. Iguchi, K.; Sahashi, A.; Khono, J.; Yamada, Y. New sesquiterpenoid hydroquinone and quinones 
from the Okinawan marine sponge (Dysidea sp.). Chem. Pharm. Bull. 1990, 38, 1121–1123. 
71. Hirsch, S.; Rudi, A.; Kashman, Y.; Loya, Y. New avarone and avarol derivatives from the marine 
sponge Dysidea cinerea. J. Nat. Prod. 1991, 54, 92–97. 
72. Crispino, A.; de Giulio, A.; de Rosa, S.; Strazzullo, G. A new bioactive derivative of avarol from 
the marine sponge Dysidea avara. J. Nat. Prod. 1989, 52, 646–648. 
73. De Giulio, A.; de Rosa, S.; di Vincenzo, G.; Strazzullo, G. Further bioactive derivative of avarol 
from Dysidea avara. Tetrahedron 1990, 46, 7971–7976. 
Mar. Drugs 2013, 11 1634 
 
 
74. Loya, S.; Tal, R.; Hizi, A.; Issacs, S.; Kashman, Y.; Loya, Y. Hexaprenoid hydroquinones, novel 
inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. J. Nat. Prod. 1993, 
56, 2120–2125. 
75. Schmitz, F.J.; Lakshmi, V.; Powell, D.R.; van der Helm, D. Arenarol and arenarone: 
Sesquiterpenoids with rearranged drimane skeletons from the marine sponge Dysidea arenaria.  
J. Org. Chem. 1984, 49, 241–244. 
76. Luibrand, R.T.; Erdman, T.R.; Vollmer, J.J.; Scheuer, P.J.; Finer, J.; Clardy, J. Ilimaquinone, a 
sesquiterpenoid quinone from a marine sponge. Tetrahedron 1979, 35, 609–612. 
77. Liu, H.; Wang, G.; Namikoshi, M.; Kobayashi, H.; Yao, X.; Cai, G. Sesquiterpene quinones from a 
marine sponge Hippospongia sp. that inhibit maturation of starfish oocytes and induce cell cycle 
arrest with HepG2 cells. Pharm. Biol. 2006, 44, 522–527. 
78. Cartè, B.; Rose, C.B.; Faulkner, D.J. 5-Epi-Ilimaquinone, a metabolite of the sponge 
Fenestraspongia sp. J. Org. Chem. 1985, 50, 2785–2787. 
79. Kazlauskas, R.; Murphy, P.T.; Warren, R.G.; Wells, R.J.; Blount, J.F. New quinones from a 
dictyoceratid sponge. Aust. J. Chem. 1978, 31, 2685–2697. 
80. Rodriguez, J.; Quinoa, H.; Riguera, R.; Peters, B.M.; Abrell, L.M.; Crews, P. The structures and 
stereochemistry of cytotoxic sesquiterpene quinones from Dactylospongia elegans. Tetrahedron 
1992, 48, 6667–6680.  
81. Capon, R.J.; MacLeod, J.K. Revision of the absolute stereochemistry of ilimaquinone. J. Org. 
Chem. 1987, 52, 5059–5060. 
82. Nambiar, M.P.; Wu, H.C. Ilimaquinone inhibits the cytotoxicities of ricin, diphtheria toxin, and 
other protein toxins in Vero cells. Exp. Cell Res. 1995, 219, 671–678. 
83. Takizawa, P.A.; Yucel, J.K.; Veit, B.; Faulkner, D.J.; Deerinck, T.; Soto, G.; Ellisman, M.; 
Malhotra, V. Complete vesiculation of Golgi membranes and inhibition of protein transport by a 
novel sea sponge metabolite, ilimaquinone. Cell 1993, 73, 1079–1090. 
84. Casaubon, R.L.; Snapper, M.L. S-adenosylmethionine reverses ilimaquinone’s vesiculation of the 
Golgi apparatus: A fluorescence study on the cellular interactions of ilimaquinone. Bioorg. Med. 
Chem. Lett. 2001, 11, 133–136. 
85. Lu, P.-H.; Chueh, S.-C.; Kung, F.-L.; Pan, S.-L.; Shen, Y.-C.; Guh, J.-H. Illimaquinone, a marine 
sponge metabolite, displays anticancer activity via GADD153-mediated pathway. Eur. J. 
Pharmacol. 2007, 556, 45–54. 
86. Guzmán, F.S.; Copp, B.R.; Mayne, C.L.; Concepcion, G.P.; Mangalindan, G.C.; Barrows, L.R.; 
Ireland, C.M. Bolinaquinone: A novel cytotoxic sesquiterpene hydroquinone from Philippine 
Dysidea sponge. J. Org. Chem. 1998, 63, 8042–804. 
87. Li, Y.; Zhang, Y.; Shen, X.; Guo, Y. A novel sesquiterpene quinone from Hainan sponge  
Dysidea villosa. Bioorg. Med. Chem. Lett. 2009, 19, 390–392. 
88. Jankam, A.; Somerville, M.J.; Hooper, J.N.A.; Brecknell, D.J.; Suksamrarna, A.; Garson, M.J. 
Dactylospongiaquinone, a new meroterpenoid from the Australian marine sponge Dactylospongia 
n. sp. Tetrahedron 2007, 63, 1577–1582. 
  
Mar. Drugs 2013, 11 1635 
 
 
89. Yong, K.W.L.; Jankam, A.; Hooper, J.N.A.; Suksamrarn, A.; Garson, M.J. Stereochemical 
evaluation of sesquiterpene quinones from two sponges of the genus Dactylospongia and the 
implication for enantioselective processes in marine terpene biosynthesis. Tetrahedron 2008, 64, 
6341–6348. 
90. Utkina, N.K.; Veselova, M.V. New sesquiterpene quinones from marine sponges of the order 
Dictyoceratida. Chem. Nat. Compd. 1990, 26, 37–40. 
91. Swersey, J.C.; Barrows, L.R.; Ireland, C.M. Mamanuthaquinone: An antimicrobial and cytotoxic 
metabolite of Fasciospongia sp. Tetrahedron Lett. 1991, 32, 6687–6690. 
92. Talpir, R.; Rudi, A.; Kashman, Y.; Loya, Y.; Hizi, A. Three new sesquiterpene hydroquinones 
from marine origin. Tetrahedron 1994, 50, 4179–4184. 
93. Poigny, S.; Huor, T.; Guyot, M.; Samadi, M. Synthesis of (−)-hyatellaquinone and revision of 
absolute configuration of naturally occurring (+)-hyatellaquinone. J. Org. Chem. 1999, 64, 
9318–9320. 
94. Bernet, A.; Schröder, J.; Seifert, K. Total synthesis of the marine sesquiterpene quinones 
hyatellaquinone and spongiaquinone. Helv. Chim. Acta 2003, 86, 2009–2020. 
95. McNamara, C.E.; Larsen, L.; Perry, N.B.; Harper, J.L.; Berridge, M.V.; Chia, E.W.; Kelly, M.; 
Webb, V.L. Anti-inflammatory sesquiterpene-quinones from the New Zealand sponge Dysidea cf. 
cristagalli. J. Nat. Prod. 2005, 68, 1431–1433. 
96. Coval, S.J.; Conover, M.A.; Mierzwa, R.; King, A.; Puar, M.S.; Phife, D.W.; Pai, J.K.;  
Burrier, R.E.; Ahn, H.S. Wiedendiol A and B, cholesteryl esther transfer protein inhibitors from 
marine sponge Xetospongia widenmayeri. Bioorg. Med. Chem. Lett. 1995, 5, 605–610. 
97. Laube, T.; Bernet, A.; Dahse, H.-M.; Jacobsen, I.D.; Seifert, K. Synthesis and pharmacological 
activities of some sesquiterpene quinones and hydroquinones. Bioorg. Med. Chem. 2009, 17, 
1422–1427.  
98. Venkateswarlu, Y.; Faulkner, D.J.; Steiner, J.L.R.; Corcoran, E.; Clardy, J. Smenochromenes, 
unusual macrocyclic sesquiterpene hydroquinone derivatives from a Seychelles sponge of the 
genus Smenospongia. J. Org. Chem. 1991, 56, 6271–6274. 
99. Goclik, E.; Konig, G.M.; Wright, A.D.; Kaminsky, R. Pelorol from the tropical marine sponge 
Dactylospongia elegans. J. Nat. Prod. 2000, 63, 1150–1152. 
100. Sullivan, B.; Djura, P.; McIntyre, D.E.; Faulkner, D.J. Antimicrobial constituents of the sponge 
Siphonodictyon coralliphagum. Tetrahedron 1981, 37, 979–982. 
101. Sullivan, B.; Faulkner, D.J.; Matsumoto, G.K.; He, C.H.; Clardy, J. Metabolites of the burrowing 
sponge Siphonodictyon coralliphagum. J. Org. Chem. 1986, 51, 4568–4573. 
102. Grube, A.; Assmann, M.; Lichte, E.; Sasse, F.; Pawlik, J.R.; Koeck, M. Bioactive metabolites from 
the caribbean sponge Aka coralliphagum. J. Nat. Prod. 2007, 70, 504–509. 
103. Kondracki, M.L.; Guyot, M. Smenospongine: A cytotoxic and antimicrobial aminoquinone 
isolated from Smenospongia sp. Tetrahedron Lett. 1987, 28, 5815–5818. 
104. Kwak, J.H.; Schmitz, F.J.; Kelly, M. Sesquiterpene quinols/quinones from the Micronesian sponge 
Petrosaspongia metachromia. J. Nat. Prod. 2000, 63, 1153–1156. 
105. Aoki, S.; Kong, D.; Matsui, K.; Kobayashi, M. Smenospongine, a spongean sesquiterpene 
aminoquinone, induces erythroid differentiation in K562 cells. Anticancer Drugs 2004, 15, 
363–369. 
Mar. Drugs 2013, 11 1636 
 
 
106. Aoki, S.; Kong, D.; Matsui, K.; Rachmat, R.; Kobayashi, M. Sesquiterpene aminoquinones, from a 
marine sponge, induce erythroid differentiation in human chronic myelogenous leukemia, K562 
cells. Chem. Pharm. Bull. 2004, 52, 935–937. 
107. Ovenden, S.P.B.; Nielson, J.L.; Liptrot, C.H.; Willis, R.H.; Tapiolas, D.M.; Wright, A.D.;  
Motti, C.A. Sesquiterpene benzoxazoles and sesquiterpene quinones from the marine sponge 
Dactylospongia elegans. J. Nat. Prod. 2011, 74, 65–68. 
108. Augustijns, P.; Annaert, P.; Heylen, P.; van den Mooter, G.; Kinget, R. Drug absorption studies of 
prodrug esters using the Caco-2 model: Evaluation of ester hydrolysis and transepithelial transport. 
Int. J. Pharm. 1998, 166, 45–53. 
109. Giannini, C.; Debitus, C.; Lucas, R.; Ubeda, A.; Paya, M.; Hooper, J.N.A.; D’Auria, M.V.  
New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile 
against human phospholipase A2 and other leukocyte functions. J. Nat. Prod. 2001, 64, 612–615. 
110. Zhang, Y.; Li, Y.; Guo, Y.; Jiang, H.; Shen, X. A sesquiterpene quinone, dysidine, from the sponge 
Dysidea villosa, activates the insulin pathway through inhibition of PTPases. Acta Pharmacol. Sin. 
2009, 30, 333–345. 
111. Diaz-Marrero, A.R.; Austin, P.; van Soest, R.; Matainaho, T.; Roskelley, C.D.; Roberge, M.; 
Andersen, R.J. Avinosol, a meroterpenoid-nucleoside conjugate with antiinvasion activity isolated 
from the marine sponge Dysidea sp. Org. Lett. 2006, 8, 3749–3752. 
112. Rodriguez, A.D.; Yoshida, W.Y.; Scheuer, P.J. Popolohuanone A and B. Two new sesquiterpenoid 
aminoquinones from Pacific sponge Dysidea sp. Tetrahedron 1990, 46, 8025–8030. 
113. Carney, J.R.; Scheuer, P.J. Popolohuanone E, a topoisomerase II inhibitor eith selective lung 
citotoxicity from Pohnpei sponge Dysidea sp. Tetrahedron Lett. 1993, 34, 3727–3730. 
114. Utkina, N.K.; Denisenko, V.A.; Krasokhin, V.B. Sesquiterpenoidd aminoquinones from marine 
sponge Dysidea sp. J. Nat. Prod. 2010, 73, 788–791. 
115. Shigemori, H.; Madono, T.; Sasaki, T.; Mikami, Y.; Kobayashi, J. Nakijiquinones A and B, new 
antifungal sesquiterpenoid quinones with an amino acid residue from an Okinawan marine sponge. 
Tetrahedron 1994, 50, 8347–8354. 
116. Kobayashi, J.; Madono, T.; Shigemori, H. Nakijiquinones C and D, new sesquiterpenoid quinones 
with a hydroxy amino acid residue from a marine sponge inhibiting c-erbB-2 kinase. Tetrahedron 
1995, 51, 10867–10874. 
117. Takahashi, Y.; Kubota, T.; Kobayashi, J. Nakijiquinones E and F, new dimeric sesquiterpenoid 
quinones from marine sponge. Bioorg. Med. Chem. 2009, 17, 2185–2188. 
118. Takahashi, Y.; Kubota, T.; Ito, J.; Mikami, Y.; Fromont, J.; Kobayashi, J. Nakijiquinones G–I, new 
sesquiterpenoid quinones from marine sponge. Bioorg. Med. Chem. 2008, 16, 7561–7564. 
119. Takahashi, Y.; Ushio, M.; Kubota, T.; Yamamoto, S.; Fromont, J.; Kobayashi, J. Nakijiquinones 
J–R, sesquiterpenoid quinones with an amine residue from Okinawan marine sponges. J. Nat. 
Prod. 2010, 73, 467–471. 
120. Stahl, P.; Kissau, L.; Mazitschek, R.; Huwe, A.; Furet, P.; Giannis, A.; Waldmann, H. Total 
synthesis and biological evaluation of the nakijiquinones. J. Am. Chem. Soc. 2001, 123, 
11586–11593. 
Mar. Drugs 2013, 11 1637 
 
 
121. Mitome, H.; Nagasawa, T.; Miyaoka, H.; Yamada, Y.; van Soest, R.W.M. Dactyloquinones A and 
B, new sesquiterpenoid quinones from the okinawan marine sponge Dactylospongia elegans.  
J. Nat. Prod. 2001, 64, 1506–1508. 
122. Mitome, H.; Nagasawa, T.; Miyaoka, H.; Yamada, Y.; van Soest, R.W.M. Dactyloquinones C, D 
and E novel sesquiterpenoid quinones, from the Okinawan marine sponge, Dactylospongia elegans. 
Tetrahedron 2002, 58, 1693–1696. 
123. Djura, P.; Stierle, D.B.; Sullivan, B.; Faulkner, D.J.; Arnold, E.V.; Clardy, J. Some metabolites of 
the marine sponges Smenospongia aurea and Smenospongia (≡Polyfibrospongia) echina. J. Org. 
Chem. 1980, 45, 1435–1441. 
124. Wright, A.E.; Rueth, S.A.; Cross, S.S. An antiviral sesquiterpene hydroquinone from the marine 
sponge Strongylophora hartmani. J. Nat. Prod. 1991, 54, 1108–1111. 
125. Cimino, G.; de Stefano, S.; Minale, L. Chromazonarol, a chroman-sesquiterpenoid from sponge 
Dysidea pallenscens. Experientia 1975, 31, 1117. 
126. Barrero, A.J.; Alvarez-Manzaneda, E.J.; Herrador, M.M.; Chahboun, R.; Galera, P. Synthesis and 
antitumoral activities of marine ent-chromazonarol and related compounds. Bioorg. Med. Chem. 
Lett. 1999, 9, 2325–2328.  
127. Song, F.; Fan, X.; Xu, X.; Wang, S.; Li, S.; Yang, Y.; Shi, J. Studies on chemical constituents of 
the brown alga Dictyopteris divaricata. Zhongguo Zhong Yao Za Zhi 2006, 31, 125–128.  
128. Hideaki, I.; Kazuaki, I.; Hisashi, Y. A new artificial cyclase for poliprenoids: Enantioselective 
total synthesis of (−)-chromazonarol, (+)-8-epi-puupehedione and (−)-11′-deoxytaondiol methyl 
ether. J. Am. Chem. Soc. 2004, 126, 11133–11123. 
129. Ravi, B.N.; Perzanowski, H.P.; Ross, R.A.; Erdman, T.R.; Scheuer, P.J.; Finer, J.; Clardy, J. 
Recent research in marine natural products: The puupehenones. Pure Appl. Chem. 1979, 51, 
1893–1900. 
130. Nasu, S.S.; Yeung, B.K.S.; Hamann, M.T.; Scheuer, P.J.; Kelly-Borges, M.; Goins, K. 
Puupehenone-related metabolites from two Hawaiian sponges, Hyrtios spp. J. Org. Chem. 1995, 
60, 7290–7292. 
131. Bourguet-Kondracki, M.L.; Debitus, C.; Guyot, M. Dipuupehedione, a cytotoxic new red dimer 
from a New Caledonian marine sponge Hyrtios sp. Tetrahedron Lett. 1996, 37, 3861–3864. 
132. Bourguet-Kondracki, M.L.; Lacombe, F.; Guyot, M. Methanol adduct of puupehenone, a 
biologically active derivative from the marine sponge Hyrtios species. J. Nat. Prod. 1999, 62, 
1304–1305. 
133. Piña, I.C.; Sanders, M.L.; Crews, P. Puupehenone congeners from an Indo-Pacific Hyrtios sponge. 
J. Nat. Prod. 2003, 66, 2–6. 
134. Ciavatta, M.L.; Gresa, M.P.L.; Gavagnin, M.; Romero, V.; Melck, D.; Manzo, E.; Guo, Y.W.;  
van Soest, R.; Cimino, G. Studies on puupehenone-metabolites of a Dysidea sp.: Structure and 
biological activity. Tetrahedron 2007, 63, 1380–1384. 
135. Robinson, S.J.; Hoobler, E.K.; Riener, M.; Loveridge, S.T.; Tenney, K.; Valeriote, F.A.;  
Holman, T.R.; Crews, P. Using enzyme assays to evaluate the structure and bioactivity of 
sponge-derived meroterpenes. J. Nat. Prod. 2009, 72, 1857–1863. 
Mar. Drugs 2013, 11 1638 
 
 
136. Xu, W.H.; Ding, Y.; Jacob, M.R.; Agarwal, A.K.; Clark, A.M.; Ferreira, D.; Liang, Z.S.; Li, X.C. 
Puupehanol, a sesquiterpene-dihydroquinone derivative from the marine sponge Hyrtios sp. 
Bioorg. Med. Chem. Lett. 2009, 19, 6140–6143. 
137. Amade, P.; Chevelot, L.; Perzanowski, H.P.; Scheuer, P.J. A dimer of puupehenone. Helv. Chim. 
Acta 1983, 66, 1672–1675. 
138. Castro, M.E.; González-Iriarte, M.; Barrero, A.F.; Salvador-Tormo, N.; Muñoz-Chápuli, R.; 
Medina, M.A.; Quesada, A.R. Study of puupehenone and related compounds as inhibitors of 
angiogenesis. Int. J. Cancer 2004, 110, 31–38. 
139. El Sayed, K.A.; Bartyzel, P.; Shen, X.; Perry, T.L.; Zjawiony, J.K.; Hamann, M.T. Marine natural 
products as antituberculosis agents. Tetrahedron 2000, 56, 949–953. 
140. Douat-Casassus, C.; Marchand-Geneste, N.; Diez, E.; Aznar, C.; Picard, P.; Geoffre, S.; Huet, A.; 
Bourguet-Kondracki, M.L.; Gervois, N.; Jotereau, F.; et al. Covalent modification of a 
melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, 
molecular modelling and immunological evaluation studies. Mol. BioSyst. 2006, 2, 240–249. 
141. Utkina, N.K.; Denisenko, V.A.; Krasokhin, V.B. Diplopuupehenone, a new unsymmetrical 
puupehenone-related dimer from the marine sponge Dysidea sp. Tetrahedron Lett. 2011, 52, 
3765–3768. 
142. Quideau, S.; Lebon, M.; Lamidey, A.M. Enantiospecific synthesis of the antituberculosis marine 
sponge metabolite (+)-puupehenone. The arenol oxidative activation route. Org. Lett. 2002, 4, 
3975–3978. 
143. Chan, J.A.; Freyer, A.J.; Carté, B.K.; Hemling, M.E.; Hofmann, G.H.; Mattern, M.R.;  
Mentzer, M.A.; Westley, J.W. Protein kinase C inhibitors: Novel spitosequiterpene aldehydes 
from a marine sponge Aka (=Siphonodictyon) coralliphagum. J. Nat. Prod. 1994, 57, 1543–1548. 
144. Utkina, N.K.; Denisenko, V.A.; Scholokova, O.V.; Virovaya, M.V.; Prokof’eva, N.G. 
Cyclosmenospongine, a new sesquiterpenoid aminoquinone from an Australian marine sponge 
Spongia sp. Tetrahedron Lett. 2003, 44, 101–102. 
145. Utkina, N.K.; Denisenko, V.A.; Scholokova, O.V.; Makarchenko, A.E. Determination of the 
absolute stereochemistry of cyclosmenospongine. J. Nat. Prod. 2003, 66, 1263–1265. 
146. Mitome, H.; Nagasawa, T.; Miyaoka, H.; Yamada, Y.; van Soest, R.W.M. A new sesquiterpenoid 
quinone and other related compounds from the okinawan marine sponge Dactylospongia elegans. 
J. Nat. Prod. 2003, 66, 46–50. 
147. Killday, K.B.; Wright, A.E. Bis(Sulfato)-cyclosiphonodictyol A, a new disulfated 
sesquiterpene-hydroquinone from a deep water collection of the marine sponge Siphonodictyon 
coralliphagum. J. Nat. Prod. 1995, 58, 958–960. 
148. Patil, A.D.; Freyer, A.J.; Killmer, L.; Offen, P.; Carte, B.; Jurewicz, A.J.; Johnson, R.K. 
Frondosins, five new sesquiterpene hydroquinone derivatives with novel skeletons from the 
sponge Dysidea frondosa: Inhibitors of interleukin-8 receptors. Tetrahedron 1997, 53, 5047–5060. 
149. Jiao, W.-H.; Huang, X.-J.; Yang, J.-S.; Yang, F.; Piao, S.-J.; Gao, H.; Li, J.; Ye, W.-C.; Yao, X.; 
Chen, W.-S.; et al. Dysidavarones A–D, new sesquiterpene quinones from the marine sponge 
Dysidea avara. Org. Lett. 2012, 14, 202–205. 
Mar. Drugs 2013, 11 1639 
 
 
150. Nakamura, H.; Kobayashi, J.; Kobayashi, M.; Ohizumi, Y.; Hirata, Y. Xestoquinone. A novel 
cardiotonic marine natural product isolated from the Okinawan sea sponge Xestospongia sapra. 
Chem. Lett. 1985, 6, 713–716. 
151. Roll, D.M.; Scheuer, P.J. Halenaquinone, a pentacyclic polyketide from a marine sponge. J. Am. 
Chem. Soc. 1983, 105, 6177–6178. 
152. Cao, S.; Foster, C.; Brisson, M.; Lazo, J.S.; Kingston, D.G.I. Halenaquinone and xestoquinone 
derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg. Med. Chem. 2005, 
13, 999–1003. 
153. Concepcion, G.P.; Foderaro, T.A.; Eldredge, G.S.; Lobkovsky, E.; Clardy, J.; Barrows, L.R.; 
Ireland, C.M. Topoisomerase II-mediated DNA Cleavage by adocia- and xestoquinones from the 
philippine sponge Xestospongia sp. J. Med. Chem. 1995, 38, 4503–4507. 
154. Schmitz, F.J.; Bloor, S.J. Xesto- and halenaquinone derivatives from a sponge, Adocia sp., from 
truk lagoon. J. Org. Chem. 1988, 53, 3922–3925. 
155. Desoubzdanne, D.; Marcourt, L.; Raux, R.; Chevalley, S.; Dorin, D.; Doerig, C.; Valentin, A.; 
Ausseil, F.; Debitus, C. Alisiaquinones and alisiaquinol, dual inhibitors of plasmodium falciparum 
enzyme targets from a new caledonian deep water sponge. J. Nat. Prod. 2008, 71, 1189–1192. 
156. Zhang, H.; Khalil, Z.G.; Capon, R.J. Fascioquinols A–F: Bioactive meroterpenes from a 
deep-water southern Australian marine sponge Fasciospongia sp. Tetrahedron 2011, 67, 
2591–2595. 
157. Standish, A.J.; Salim, A.A.; Zhang, H.; Capon, R.J.; Morona, R. Chemical inhibition of bacterial 
protein tyrosine phosphatase suppresses capsule production. PLoS One 2012, 7, e36312. 
158. Standish, A.J.; Salim, A.A.; Capon, R.J.; Morona, R. Dual inhibition of DNA polymerase PolC 
and protein tyrosine phosphatase CpsB uncovers a novel antibiotic target. Biochem. Biophys. Res. 
Commun. 2013, 430, 167–172. 
159. Tasdemir, D.; Concepción, G.P.; Mangalindan, G.C.; Harper, M.K.; Hajduc, E.; Ireland, C.M. 
New terpenoids from a Cacospongia sp. from the Philippines. Tetrahedron 2000, 56, 9025–9030. 
160. Murray, L.M.; Johnson, A.; Diaz, M.C.; Crews, P. Geographic variation in the tropical marine 
sponge Jaspis cf. johnstoni: An unexpected source of new terpene-benzenoids. J. Org. Chem. 
1997, 62, 5638–5641. 
161. Rubio, B.K.; van Soest, R.W.M.; Crews, P. Extending the record of meroditerpenes from 
Cacospongia marine sponges. J. Nat. Prod. 2007, 70, 628–631. 
162. Loll, P.J.; Axelsen, P.H. The structural biology of molecular recognition by vancomycin.  
Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 265–289. 
163. Carroll, J.; Jonsson, E.N.; Ebel, R.; Hartman, M.S.; Holman, T.R.; Crews, P. Probing 
sponge-derived terpenoids for human 15-lipoxygenase inhibitors. J. Org. Chem. 2001, 66, 
6847–6851. 
164. Williams, D.E.; Telliez, J.B.; Liu, J.; Tahir, A.; van Soest, R.; Andersen, R.J. Meroterpenoid 
MAPKAP (MK2) inhibitors isolated from the Indonesian marine sponge Acanthodendrilla sp.  
J. Nat. Prod. 2004, 67, 2127–2129. 
  
Mar. Drugs 2013, 11 1640 
 
 
165. Cichewicz, R.H.; Kenyon, V.A.; Whitman, S.; Morales, N.M.; Arguello, J.F.; Holman, T.R.; 
Crews, P. Redox inactivation of human 15-lipoxygenase by marine-derived meroditerpenes and 
synthetic chromanes: Archetypes for a unique class of selective and recyclable inhibitors. J. Am. 
Chem. Soc. 2004, 126, 14910–14920. 
166. Braekman, J.C.; Daloze, D.; Hulot, G.; Tursch, B.; Declercq, J.P.; Germain, G.; van Meerssche, M. 
Chemical studies of marine invertebrates. XXXVII. Three novel meroditerpenoids from the 
sponge Strongylophora durissima. Bull. Soc. Chim. Belg. 1978, 87, 917–926. 
167. Salva, J.; Faulkner, D.J. Metabolites of the sponge Strongylophora durissima from Maricaban 
Island, Philippines. J. Org. Chem. 1990, 55, 1941–1943. 
168. Balbin-Oliveros, M.; Edrada, R.; Proksch, P.; Wray, V.; Witte, W.M.; van Soest, R.W.M. A new 
meroditerpenoid dimer from an undescribed Philippine marine sponge of the genus 
Strongylophora. J. Nat. Prod. 1998, 61, 948–952. 
169. Liu, H.; Namikoshi, M.; Akano, K.; Kobayashi, H.; Nagai, H.; Yao, X. Seven new 
meroditerpenoids, from the marine sponge Strongylophora strongylata, that inhibited the 
maturation of starfish oocytes. J. Asian Nat. Prod. Res. 2005, 7, 661–670. 
170. Warabi, K.; Patrick, B.O.; Austin, P.; Roskelley, C.D.; Roberge, M.; Andersen, R.J. 
Strongylophorine-26, an inhibitor of cancer cell invasion: SAR revealed by synthesis of analogues. 
J. Nat. Prod. 2007, 70, 736–740. 
171. McHardy, L.M.; Warabi, K.; Andersen, R.J.; Roskelley, C.D.; Roberge, M. Strongylophorine-26, 
a Rho-dependent inhibitor of tumor cell invasion that reduces actin stress fibers and induces 
nonpolarized lamellipodial extensions. Mol. Cancer Ther. 2005, 4, 772–778. 
172. Shen, Y.C.; Prakash, C.V. Two new acetylenic derivatives and a new meroditerpenoid from a 
Taiwanese marine sponge Strongylophora durissima. J. Nat. Prod. 2000, 63, 1686–1688. 
173. Warabi, K.; McHardy, L.M.; Matainaho, L.; van Soest, R.W.M.; Roskelley, C.D.; Roberge, M.; 
Andersen, R.J. Strongylophorine-26, a new meroditerpenoid isolated from the marine sponge 
Petrosia (Strongylophora) corticata that exhibits anti-invasion activity. J. Nat. Prod. 2004, 67, 
1387–1389. 
174. Mohammed, K.A.; Jadulco, R.C.; Bugni, T.S.; Harper, M.K.; Sturdy, M.; Ireland, C.M.; 
Strongylophorines: Natural product inhibitors of hypoxia-inducible factor-1 transcriptional 
pathway. J. Med. Chem. 2008, 51, 1402–1405. 
175. Sasaki, S.; Tozawa, T.; van Wagoner, R.M.; Ireland, C.M.; Harper, M.K.; Satoh, T. 
Strongylophorine-8, a pro-electrophilic compound from the marine sponge Petrosia 
(Strongylophora) corticata, provides neuroprotection through Nrf2/ARE pathway. Biochem. 
Biophys. Res. Commun. 2011, 415, 6–10. 
176. Bae, J.M.; Jeon, J.E.; Lee, Y.J.; Lee, H.S.; Sim, C.J.; Oh, K.B.; Shin, J.H. Sesterterpenes from the 
tropical sponge Coscinoderma sp. J. Nat. Prod. 2011, 74, 1805–1811. 
177. Alea, G.V.; Carroll, A.R.; Bowden, B.F. Coscinoquinol, a new cytotoxic sesterterpene from a 
dictyoceratid sponge, Coscinoderma sp. Aust. J. Chem. 1994, 47, 191–194. 
178. Kernan, M.R.; Faulkner, D.J. Sesterterpene sulfates from a sponge of the family Halichondriidae. 
J. Org. Chem. 1988, 53, 4574–4578. 
Mar. Drugs 2013, 11 1641 
 
 
179. Loukaci, A.; Le Saout, I.; Samadi, M.; Leclerc, S.; Damiens, E.; Meijer, L.; Debitus, C.; Guyot, M. 
Coscinosulfate, a CDC25 phosphatase inhibitor from the sponge Coscinoderma mathewsi. Bioorg. 
Med. Chem. 2001, 9, 3049–3054. 
180. Kimura, J.; Ishizuka, E.; Nakao, Y.; Yoshida, W.Y.; Scheuer, P.J.; Kelly-Borges, M. Isolation of 
1-methylherbipoline salts of halisulfate-1 and of suvanine as serine protease inhibitors from a 
marine sponge, Coscinoderma mathewsi. J. Nat. Prod. 1998, 61, 248–250. 
181. Lee, H.S.; Lee, T.H.; Yang, S.H.; Shin, H.J.; Shin, J.; Oh, K.B. Sesterterpene sulfates as isocitrate 
lyase inhibitors from tropical sponge Hippospongia sp. Bioorg. Med. Chem. Lett. 2007, 17, 
2483–2486. 
182. Shin, D.S.; Lee, T.H.; Lee, H.S.; Shin, J.; Oh, K.B. Inhibition of infection of the rice blast fungus 
by halisulfate 1, an isocitrate lyase inhibitor. FEMS Microbiol. Lett. 2007, 272, 43–47. 
183. De Marino, S.; Festa, C.; D’Auria, M.V.; Bourguet-Kondracki, M.-L.; Petek, S.; Debitus, C.; 
Andres, R.M.; Terencio, M.C.; Paya, M.; Zampella, A. Coscinolactams A and B: New 
nitrogen-containing sesterterpenoids from the marine sponge Coscinoderma mathewsi exerting 
anti-inflammatory properties. Tetrahedron 2009, 65, 2905–2909. 
184. Baratte, B.; Meijer, L.; Galaktionov, K.; Beach, D. Screening for antimitotic compounds using the 
cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein 
kinase. Anticancer Res. 1992, 12, 873–880. 
185. Isaacs, S.; Kashman, Y. Shaagrockol B and C; two hexaprenylhydroquinone disulfates from the 
Red Sea sponge Toxiclona toxius. Tetrahedron Lett. 1992, 33, 2227–2230. 
186. Isaacs, S.; Hizi, A.; Kashman, Y. Toxicols A–C and toxiusol—New bioactive hexaprenoid 
hydroquinones from Toxiclona toxius. Tetrahedron 1993, 49, 4275–4282. 
187. Blackburn, C.L.; Hopmann, C.; Sakowicz, R.; Berdelis, M.S.; Goldstein, L.S.B.; Faulkner, D.J. 
Adociasulfates 1–6, inhibitors of kinesin motor proteins from the sponge Haliclona (aka Adocia) sp. 
J. Org. Chem. 1999, 64, 5565–5570. 
188. Blackburn, C.L.; Faulkner, D.J. Adociasulfate 10, a new merohexaprenoid sulfate from the sponge 
Haliclona (aka Adocia) sp. Tetrahedron 2000, 56, 8429–8432. 
189. Kalaitzis, J.A.; Leone, P.A.; Harris, L.; Butler, M.S.; Ngo, A.; Hooper, J.N.A.; Quinn, R.J. 
Adociasulfates 1, 7, and 8: New bioactive hexaprenoid hydroquinones from the marine sponge 
Adocia sp. J. Org. Chem. 1999, 64, 5571–5574. 
190. West, L.M.; Faulkner, D.J. Hexaprenoid hydroquinones from the sponge Haliclona (aka Adocia) sp. 
J. Nat. Prod. 2006, 69, 1001–1004. 
191. Kalaitzis, J.A.; Quinn, R.J. Adociasulfate-9, a new hexaprenoid hydroquinone from the Great 
Barrier Reef sponge Adocia aculeata. J. Nat. Prod. 1999, 62, 1682–1684. 
192. Barton, N.R.; Goldstein, L.S.B. Going mobile: Microtubule motors and chromosome segregation. 
Proc. Natl. Acad. Sci. USA 1996, 93, 1735–1742. 
193. Hirokawa, N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. 
Science 1998, 279, 519–526. 
194. Crews, P.; Harrison, B. New triterpene-ketides (merotriterpenes), haliclotriol A and B, from an 
indo-pacific Haliclona sponge. Tetrahedron 2000, 56, 9039–9046. 
195. Trianto, A.; Hermawan, I.; de Voogd, N.J.; Tanaka, J. Halioxepine, a new meroditerpene from an 
Indonesian sponge Haliclona sp. Chem. Pharm. Bull. 2011, 59, 1311–1313. 
Mar. Drugs 2013, 11 1642 
 
 
196. Fisch, K.M.; Böhm, V.; Wright, A.D.; König, G.M. Antioxidative meroterpenoids from the brown 
alga Cystoseira crinite. J. Nat. Prod. 2003, 66, 968–975. 
197. Williams, D.E.; Steinø, A.; de Voogd, N.J.; Mauk, A.G.; Andersen, R.J. Halicloic acids A and B 
isolated from the marine sponge Haliclona sp. collected in the Philippines inhibit indoleamine 
2,3-dioxygenase. J. Nat. Prod. 2012, 75, 1451–1458. 
198. Fukami, A.; Ikeda, Y.; Kondo, S.; Naganawa, H.; Takeuchi, T.; Furuya, S.; Hirabayashi, Y.; 
Shimoike, K.; Hosaka, S.; Watanabe Y.; Umezawa, K. Akaterpin, a novel bioactive triterpene 
from the marine sponge Callyspongia sp. Tetrahedron Lett. 1997, 38, 1201–1202. 
199. Gray, C.A.; de Lira, S.P.; Silva, M.; Pimenta, E.F.; Thiemann, O.H.; Oliva, G.; Hajdu, E.; 
Andersen, R.J.; Berlinck, R.G.S. Sulfated meroterpenoids from the Brazilian sponge  
Callyspongia sp. are inhibitors of the antileishmaniasis target adenosine phosphoribosyl 
transferase. J. Org. Chem. 2006, 71, 8685–8690. 
200. Hooper, G.J.; Davies-Coleman, M.T. Sesquiterpene hydroquinones from the South African soft 
coral Alcyonium fauri. Tetrahedron Lett. 1995, 36, 3265–3268. 
201. Sheu, J.H.; Su, J.H.; Sung, P.J.; Wang, G.H.; Dai, C.F. Novel meroditerpenoid-related metabolites 
from the formosan soft coral Nephthea chabrolii. J. Nat. Prod. 2004, 67, 2048–2052. 
202. Su, J.H.; Ahmed, A.F.; Sung, P.J.; Wu, Y.C.; Sheu, J.H. Terpenoid-related metabolites from a 
formosan soft coral Nephthea Chabrolii. J. Nat. Prod. 2005, 68, 1651–1655. 
203. Su, J.H.; Dai, C.F.; Huang, H.H.; Wu, Y.C.; Sung, P.J.; Hsu, C.H.; Sheu, J.H. Terpenoid-related 
metabolites from a Formosan soft coral Nephthea chabrolii. Chem. Pharm. Bull. 2007, 55, 
594–597. 
204. Chen, J.W.; Luo, Y.L.; Hwang, M.J.; Peng, F.C.; Ling, K.H.J. Territrem B, a tremorgenic 
mycotoxin that inhibits acetylcholinesterase with a noncovalent yet irreversible binding 
mechanism. Biol. Chem. 1999, 274, 34916−34923. 
205. Cueto, M.; MacMillan, J.B.; Jensen, P.R.; Fenical, W. Tropolactones A–D, four meroterpenoids 
from a marine-derived fungus of the genus Aspergillus. Phytochemistry 2006, 67, 1826–1831. 
206. Cohen, E.; Koch, L.; Myint Thu, K.; Rahamim, Y.; Aluma, Y.; Ilan, M.; Yarden, O.; Carmeli, S. 
Novel terpenoids of the fungus Aspergillus insuetus isolated from the Mediterranean sponge 
Psammocinia sp. collected along the coast of Israel. Bioorg. Med. Chem. 2011, 19, 6587–6593. 
207. Lopez-Gresa, M.P.; Cabedo, N.; Gonzalez-Mas, M.C.; Ciavatta, M.L.; Avila, C.; Primo, J. 
Terretonins E and F, inhibitors of the mitochondrial respiratory chain from the marine-derived 
fungus Aspergillus insuetus. J. Nat. Prod. 2009, 72, 1348–1351. 
208. Zhou, Y.; Mándi, A.; Debbab, A.; Wray, V.; Schulz, B.; Müller, W.E.G.; Lin, W.H.; Proksch, P.; 
Kurtán, T.; Aly, A.H. New austalides from the sponge-associated fungus Aspergillus sp. Eur. J. 
Org. Chem. 2011, 2011, 6009–6019. 
209. Bugni, T.S.; Abbanat, D.; Bernan, V.S.; Malese, W.M.; Greenstein, M.; van Wagoner, R.;  
Ireland, C.M. Yanuthones: Novel metabolites from a marine isolate of Aspergillus niger. J. Org. 
Chem. 2000, 65, 7195–7200. 
210. Sanchez, J.F.; Somoza, A.D.; Kellerc, N.P.; Wang, C.C.C. Advances in Aspergillus secondary 
metabolite research in the post-genomic era. Nat. Prod. Rep. 2012, 29, 351–371. 
Mar. Drugs 2013, 11 1643 
 
 
211. Lo, H.; Entwistle, R.; Guo, C.; Ahuja, M.; Szewczyk, E.; Hung, J.; Chiang, Y.; Oakley, B.R.; 
Wang, C.C.C. Two separate gene clusters encode the biosynthetic pathway for the meroterpenoids 
austinol and dehydroaustinol in Aspergillus nidulans. J. Am. Chem. Soc. 2012, 134, 4709–4720. 
212. Guo, C.; Knox, B.P.; Chiang, Y.; Lo, H.; Sanchez, J.F.; Lee, K.; Oakley, B.R.; Bruno, K.S.;  
Wang, C.C.C. Molecular genetic characterization of a cluster in A. terreus for biosynthesis of the 
meroterpenoid Terretonin. Org. Lett. 2012, 14, 5684–5687. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
